Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies

Ali Salimi-Jeda a,⁎, Sina Abbassi b, Atieh Mousavizadeh c, Maryam Esghaie a, Farah Bakheerat-Salim a, Farhad Jeddi d, Maryam Shafeaati e, Asghar Abdoli f,g

a Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
b Department of Anesthesiology, Faculty of Medical Science, Tehran University of Medical Science, Tehran, Iran
c Department of Virology, Faculty of Medical Science, Tarbiat Modares University, Tehran, Iran
d Department of Medical Genetics and Pathology, Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
e Department of Microbiology, Jahrom Branch, Islamic Azad University, Fars, Iran
f Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran

⁎ Corresponding authors.
E-mail addresses: salimi.a@iums.ac.ir (A. Salimi-Jeda), a_abdoli@pasteur.ac.ir (A. Abdoli).

A R T I C L E   I N F O
Keywords:
SARS-CoV-2
COVID-19
Emerging Variants
Pathogenesis
Immune Responses
Therapy
Vaccine

A B S T R A C T
More than a year after the SARS-CoV-2 pandemic, the Coronavirus disease 19 (COVID-19) is still a major global challenge for scientists to understand the different dimensions of infection and find ways to prevent, treat, and develop a vaccine. On January 30, 2020, the world health organization (WHO) officially announced this new virus as an international health emergency. While many biological and mechanisms of pathogenicity of this virus are still unclear, it seems that cytokine storm resulting from an immune response against the virus is considered the main culprit of the severity of the disease. Despite many global efforts to control the SARS-CoV-2, several problems and challenges have been posed in controlling the COVID-19 infection. These problems include the various mutations, the emergence of variants with high transmissibility, the short period of immunity against the virus, the possibility of reinfection in people improved, lack of specific drugs, and problems in the development of highly sensitive and specific vaccines. In this review, we summarized the results of the current trend and the latest research studies on the characteristics of the structure and genome of the SARS-CoV-2, new mutations and variants of SARS-CoV-2, pathogenicity, immune response, virus diagnostic tests, potential treatment, and vaccine candidate.

1. Introduction

SARS-CoV-2 is the third member of the coronavirus family, which is highly pathogenic in the human population and causes COVID-19 in the upper respiratory tract that has been hitherto responsible globally for more than 220,563,227 confirmed cases of infection and more than 4,565,483 deaths [1]. The coronaviridae family contains 27–34 kilobases positive-sense and single-strand RNA, which are the largest genomes among RNA viruses, but unlike other RNA viruses, it has been proven that coronaviridae family possesses the proof-reading capability [2]. Coronaviruses include four genera: alpha-CoV, beta-CoV, gamma-CoV, and delta-CoV. These genera can cause an infection in humans and animals with a high recombination rate, causing various diseases, including respiratory syndrome, renal, enteric, and neurological disorders. Seven pathogenic strains which can cause mild to severe infections in humans belong to coronaviridae family [3–4].
On January 30th, the World Health Organization (WHO) declared the 2019-nCoV (novel coronavirus) outbreak as a global concern. On February 11th 2020, the 2019-nCoV was officially renamed SARS-CoV-2. Eventually, the WHO recognized these virus outbreaks as a pandemic in March 2020 [5]. As it has been reported that some initial infected people had been exposed to the seafood market in Wuhan, China, in December 2019, some scientists are pro and con of SARS-CoV-2 as a zoonotic origin virus [6]. However, due to the lack of sufficient evidence, the first reservoir of SARS-CoV remains unknown. SARS-CoV-2 is highly contagious, and transmits through droplets, direct contact, and contact with infected objects [7]. The genetic similarity of SARS-CoV-2 with MERS-CoV and SARS-CoV is 50% and 79%, respectively [8–9]. The primary target of SARS-CoV-2 is the lower respiratory tract. Although some common flu-like illness symptoms of COVID-19 such as dry cough, fever, fatigue, aches, and pains are similar to the symptoms of two older coronaviruses, some new symptoms such as loss of taste or smell, dry mouth, dyspnea, gastrointestinal disorders, neurological symptoms, and cutaneous manifestations are introduced day by day [10–12]. SARS-CoV-2 can cause asymptomatic to mild respiratory infections, pneumonia, as well as serious health problems such as acute respiratory distress syndrome (ARDS) after increased activated T lymphocytes and mononuclear macrophages macrophage-related proinflammatory cytokines production, “cytokine storm”, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and IL-1β, IL-4, IL-7, IL-10, IL-17, IFN-γ, Transforming growth factor-β (TGF-β), and IL-8. Chemokine responses and inflammatory cell infiltration occur seven to ten days after the beginning of symptoms, leading to increased risk of vascular hyperpermeability, multi-organ failure, and eventually, death following uncontrolled conditions [13–16]. Recently, some unique symptoms have been reported in infected patients with SARS-CoV-2: rhinorrhea, sore throat, diarrhea, vomiting, smell and loss of taste, myalgia, and sneezing [17–19]. In a cohort study carried out by Xiaobo Yang et al. [20], it has been reported that pyrexia is the typical symptom of SARS-CoV-2 pneumonia; however, this sign was not detected in all cases. As COVID-19 can damage leucocytes, leucopenia was detected in more than 80% of severe patients. COVID19 in adult patients is more severe than in younger individuals due to the increased epithelial expression of ACE receptors in the respiratory and gastrointestinal tract [21] (Fig. 2). COVID19 in pediatrics has often no symptoms or has mild symptoms and, therefore, has a critical role in spreading the SARS-CoV-2 infection [22]. Although the immunity profile against COVID-19 is not wholly determined, it seems that innate immunity has an essential role in the antiviral activity and mild or severe symptoms of COVID-19 [23].

Unfortunately, despite growing studies, there is no effective drug or treatment for COVID-19 pandemic disease, and patients are being cured by supportive or unspecific treatments [24]. Most vaccine leaders are currently developing vaccines for SARS-CoV-2. Hitherto, eight vaccines have been approved for full use, eleven authorized in early or limited use, and many candidate vaccines are in various phases of vaccine design [25–26]. Although research on various aspects of nature and pathogenicity of the virus is ongoing, the lack of sufficient information and mutations of the virus genome and new variants have made a barrier to reach specific treatment options and the potency of vaccine development [27]. Thus, we here review the literature on the structure, genome organization, and variants of SARS-CoV-2, its pathogenicity, the most important clinical features, new mutations and variants of SARS-CoV-2, host-cell interactions, immune responses, diagnostic tests, potential treatments, and vaccines candidates to help improve the symptoms of COVID-19 infection to reach specific treatment options, as well as a vaccine.

2. SARS-CoV-2 structure and genome organization

Understanding the SARS-CoV-2 structure and genome organization has a pivotal role in determining the mechanisms of viral replication, infectivity, and proteins that induce host immune responses that could help find the potential drugs for treatment and vaccine development for the prevention of COVID-19 [28–30]. It has been demonstrated that the isolated positive-sense single-stranded RNA with a genome size of 29.9 kb of SARS-CoV-2 has 88% similarity to the sequence of viruses isolated from infected bats with SARS-like coronaviruses [31–32]. The SARS-CoV-2 genome contains 12 functional open reading frames (ORFs) expressing 12 proteins from 11 protein-coding genes [33–34] (Fig. 1). After entry of SARS-CoV-2 into host cells, the viral genome act as messenger RNA (mRNA) and is translated by host ribosomes. Sixteen nonstructural proteins (NSPs) are encoded via two large polyproteins, pp1a/pp1ab, from 5′-two-third of the CoVs genome. Two viral proteases named 3c-like protease and papain-like protease are responsible for processing these polypeptides to produce NSPs. Four structural proteins and accessory proteins are encoded by open reading frames (ORFs) from the 3′ one-third of the genome from a set of nested subgenomic RNAs (sgRNAs) beginning from a negative-sense RNA intermediate. About 60 to 140 nm in diameter SARS-CoV-2 virion structure consists of four structural proteins, including spike surface glycoprotein (S), nucleocapsid protein (N), membrane protein (M), and envelope protein (E), essential for viral assembly and infection [35–37] (Fig. 1). Accessory proteins are not necessary for coronavirus replication but are involved in the viral pathogenicity by modulating the interferon signaling pathway [38].

The 150 kDa trimer crown-like spikes protein is cleaved into S1 and S2 subunits. The type of cell and cellular tropism is determined by S1 part, while S2 is responsible for viral fusion in host cells. CoVs proteins classified in class I fusion proteins require protease cleavage to be functional. A single region named receptor-binding domain (RBD), located in the S1 subunit, is independently responsible for host-cell interaction in beta coronaviruses [39–40]. Using the cellular proteases by CoVs is related to the strain of the virus and the cell type. One or various types of proteases like human airway trypsin-like protease (HAT), transmembrane protease serine protease-2, 4 (TMPRSS-2, 4), cathepsins, furin, and trypsin can promote CoV S proteins cleavage; however, the roles of TMPRSS-2 and Furin in cleavage of SARS-CoV 2 are demonstrated [41–43]. S protein in some CoVs plays an essential role in virus-cell fusion. It can mediate syncytia forming, considered a major strategy to virus cell-to-cell transmission, and impairs the function of neutralizing antibodies. S protein has been considered an ideal option for vaccine design. Antibodies can disturb the protein S-cell binding and also neutralize the virus [44].

The highly phosphorylated N protein, which has the highest expression in host cells, is structurally bound to the genome and plays an indispensable role in the replication cycle process. Membrane protein M, which is the most prevalent structural protein, forms the shape of the envelope and helps the completion of the virus assembly process by binding to nucleocapsid N. IgG antibodies against SARS-CoV-2 N protein can be detectable in serum four days after onset of the disease. The E protein is a structural protein that acts as an ion channel [45–46].

Many functions associated with NSPs have remained unclear; however, several features are relevant to viral replication and subgenomic RNAs (e.g., NSP15). The Nsp14 with exonuclease activity can eliminate the nucleoside analogs (NAs) incorporated into viral RNA and reduce their efficacy. Due to the critical role of Viral RNA-dependent RNA polymerases (RdRp) along with other major enzymes in the RNA virus’s replication cycle and virus pathogenesis, they have been seen to be a superior choice to design efficient drugs to prevent or treat several viral diseases. With over 25 approved drugs or clinical trials of NAs for the initial promising treatment for a wide range of diseases. However, in coronaviruses, exonuclease domains (ExoN) are a serious barrier to reach appropriate NA drugs because resistance emerges against many of these antivirals. Despite this impairing mechanism, NAs can still be considered an efficient choice of medicines in CoVs, because of their highly conserved RdRps, and their special structural conservation of nucleotide-binding sites. The ExoN interaction with Nsp12, Nsp7, and Nsp8 promotes proofreading activity. Owing to the insignificant structural and
functional differences between SARS-CoV and SARS-CoV-2 RdRps, the last analysis for virus structure and function may be helpful for future studies [47–48].

It is worth mentioning that some significant dissimilarities between the novel coronavirus and other CoVs genomes, such as Spike proteins, ORF8, and ORF3a proteins, may make differences in the ability of SARS-CoV-2 transmission and pathogenicity [35]. Khailany et al. [49] found 116 mutations in the genome of SARS-CoV-2. The most prevalent mutation was seen in 29095C>T in the N gene, 8782C>T in the ORF1ab gene, and 28144 T>C in the ORF8 gene. The result of phylogenetic tree analysis has shown that the genetic sequences of coronavirus can be mutated because of the immunological pressure among people around the world. It presumably makes the virus easier to transmit. However, many aspects of SARS-CoV-2 pathogenicity and genome function are still unclear [50].

3. SARS-CoV-2 mutations and variants

Mutations in the virus genome have an important influence on diagnosing and treating infection and vaccine development, as well as virus prevention. Since S protein of SARS-CoV-2 is the primary target in vaccine design, mutations of this gene in regions that interact with the host cell’s angiotensin-converting enzyme 2 (ACE-2) receptor can reduce vaccines’ effectiveness against the virus. Although SARS-CoV-2, unlike many other RNA viruses, has a low sequence diversity due to the proofreading activity, genetic recombination that is caused by nsp14 3′-to-5′ exoribonuclease (Nsp14-ExoN) activity is a common event in the replication of the virus [51–52]. Hence, the generation of virus diversity and emerging variants should be monitored in vaccinated and non-vaccinated positive cases.

A clade is a group of different virus lineages that forms from evolves over time. From the beginning of the SARS-CoV-2 pandemic, two major lineages of the virus, L and S, were identified based on two single nucleotide polymorphisms in the ORF1ab and ORF8 the virus genome [53]. Then, with further analysis on more genome sequences of the virus, they were divided into three variants A, B, and C, based on amino acid changes and outbreaks [54]. Before the naming of SARS-CoV-variants by the WHO, there were some databases and softwares by different nomenclature for real-time tracking of SARS-CoV-2 evolution and clades distribution by assessing the whole genomic sequences of virus in global such as Nextstrain, GISAID, PANGOLIN, and other web sites such as CoVariants [55–58]. According to these databases, Nextstrain had identified 11 major clades (19A, 19B, and 20A–20I) as of January 2021 [55], GISAID had identified eight global clades (S, O, L, V, G, GH, GR, and GV) [56], and PANGOLIN had identified six major lineages (A, B, B.1, B.1.1, B.1.177, B.1.1.7) as of February 2021 [57]. Using these tools could be useful for the assessment of the novel variant distribution and the impact of mutations on virus transmissibility, Clinical
features, and also on the performance of antiviral drugs and the risk of escape from vaccines [59] (Table 1).

From December 2019 to October 30, 2021, more than 3,215,645 SARS-CoV-2 genomic sequences have been reported by different countries [60]. A phylogenetic analysis of SARS-CoV-2 genomes showed that they are under evolutionary selection in the human host across different regions of the world [54] and these mutants can daily transport to other provinces and countries by passengers. Comparative analysis of these SARS-CoV-2 genomes has shown that there are thousands of missense mutations, including synonymous and deletions or insertions in the non-coding, in-frame, or stop codon regions of variants. For example, Koyama et al.’s study on 10,022 SARS-CoV-2 genomes from 68 countries revealed 65,776 variants with 5775 distinct variants and 2969 missense mutations [61]. Studies also showed that the most frequent mutations were in S, ORF1ab, ORF8, and N genes [49]. Nagy A. et al.’s study showed that mutations in the ORF8, NSP6, ORF3a, NSP4, and N regions were correlated with mild outcomes. Mutations in the spike (S), RdRP, 3′-5′ exonuclease, ORF3a, NSP2, and N were associated with inferior outcomes, and mutations in the S and NSP7 leading to severe outcomes with low prevalence [62]. There are many most prevalent forms of SARS-CoV-2 variants due to their mutations that lead to more transmissibility of these strains for example the D614G mutation [52], S477N in EU2 variant [63], L452R in 20C [64], and S439K in 20A variant [63.65] that are located in the receptor-binding domain (RBD) of Spike protein and important to ACE-2 binding and antibody recognition, that may increase ACE-2 binding leading to higher levels of virus RNA [66], the resistance to multiple antibodies [67], escaped neutralization and enhanced virion infectivity [64,68]. D614 G mutation emerges early during the pandemic, and viruses containing G614 are called the “G clade” by GISAID, due to the replacement of glycine (G) instead of aspartic acid (D) in the 614th amino acid [52]. Meanwhile, S677H mutation in 20G (“20C-US”) and P681H in B.1.1.7 variants that are close to the furin binding pocket (polybasic site) and important for S1/S2 cleavage [69], as well as the presence of a proline in the S:Q677P mutation in 20G, could influence the cleavage of S1/S2 [69]. However, studies have shown that mutations near a furin cleavage site in the spike protein could cause mild symptoms in infected individuals [70].

According to the WHO, SARS-CoV-2 was characterized into two variants, including Variants of Concern (VOC) and Variants under Investigation (VUI) or Variants of interest (VRI), based on the significant genomic changes and emergency in increasing the risk to global public health (Table 1). Hitherto WHO has detected four Variants of Concern (VOC) including B.1.1.7, B.1.351 [71], P.1 [72], and B.1.617.2, which are recently labeled as Greek Alphabet Alpha, Beta, Gamma, and Delta, respectively. Also, eight Variants of interest (VRI), including B.1.427/ B.1.429, P.2, B.1.525, P.3, B.1.526, B.1.617.1, C.37, and B.1.621 are detected and labeled by Greek Alphabet from Epsilon to Mu [60,73] (Table 1).

However, despite the high transmissibility and mild symptoms of infection by mutated variants, access to herd immunity seems closer if people at high risk are vaccinated [74]. Since mutations may lead to the escape from immune recognition, understanding the molecular evolution of SARS-CoV-2 is pivotal, and the emergence of variants with different mutations should be taken into account during the development of vaccines. When seeing emerging variants of the virus, several points should be considered including, identifying mutations of the new variant to survey their effect on the diagnosis of the virus, its rate of spread and infectivity compared to previous variants, as well as the effect of new mutations on the efficacy of the produced vaccines [75].

4. Pathogenesis

In the initial phase of COVID-19 infection, following the SARS-CoV-2 infiltration to the lung parenchyma, the S glycoprotein of the virus binds to the ACE-2 receptor of the host cell. By interacting the RBD of subunit S1 with ACE-2 and cleavage at S1 and S2 by transmembrane protease serine protease-2 (TMPRSS2) and Furin, the S2 subunit mediates the fusion of virus and endosomal cell membrane and release the viral genome into the cytoplasm and continue the replication and cell-to-cell spreading [41–42]. Furthermore, studies have demonstrated that SARS-CoV-2 spike protein integrin-binding motif (arginine-glycine-aspartate-spase (RGD)) binds to α5β1 integrins, and ACE-2/α5β1 facilitates entry into host cells [82–83]. By entering the peripheral blood in this phase, the virus causes viremia in humans. In the second phase (Pulmonary phase), with the onset of the inflammatory response, apoptosis of alveolar cells, endothelial and epithelial permeability, edema, fluid accumulation, thrombus (Adhesion, activation, and aggregation of platelets) occur. Consequently, by releasing the pro-inflammatory molecules, vasoconstriction, neutrophil recruitment, Neutrophil extracellular traps (NETosis) [84–85], cell necrosis, and tissue damage, the pulmonary symptoms including impaired gas exchange, hypoxemia (Saturation of oxygen (SpO2) < 94%), impaired carbon dioxide excretion, respiratory failure, and acute respiratory distress syndrome (ARDS) occur [86–87]. Finally, in the third phase (hyperinflammation phase), symptoms are exacerbated by systemic inflammation and inflammatory-induced damage to distant organs due to the increased plasma pro-inflammatory cytokines ‘Cytokine storm’ [88] (Fig. 2).

After that, all organs that express ACE-2 and TMPRSS2, including the gastrointestinal tract, kidneys, heart, and lungs, can be the potential target for virus attack [89]. It is suggested that the virus begins a second attack, which resulted in the severity condition in patients between 7 and 14 days after symptom onset. During this period, the notable reduction in lymphocyte count and the increase in the production of the inflammatory cytokines exacerbate the severity of the infection (Fig. 2).

According to the Centers for Disease Control and Prevention (CDC) report, although all individuals are susceptible to the SARS-CoV-2, the infectivity ratio in the 18–29 age group is about three times higher than in 5 to 17 age reference group and one times higher than in other adults. The rate of hospitalization and death rate increases by nearly 2 and 3 times for each age group by 10 years compared to the reference group, respectively. For example, the death rates in the age group of 18–29, 30–39, 40–49, 50–64, and 65–74 are 15, 45, 130, 400, and 1100 times higher than the reference age group, respectively [90–91]. According to the studies, the COVID-19 severe cases ratio, Crude case fatality rate (CFR), and Case fatality rate in patients are 15.7%, 1.4–6.9%, and 11%, respectively [16].

The common symptoms of COVID-19 include sore throat, cough, fever, fatigue, headache, malaise, Myalgia, Chest distress, gastrointestinal disorders, diarrhea, loss of taste or smell, breathing difficulties, myocarditis, neurological symptoms, and cutaneous manifestations. Severe cases include pneumonia, cardiovascular implications, heart failure, viral sepsis [92], bacterial co-infection [93], severe acute respiratory syndrome, and death, especially in high-risk groups and comorbid conditions such as chronic obstructive pulmonary disease (COPD), Hypertension, type 2 diabetes, and myocardial infarction [10,17,79,94–97].

In addition to severe pneumonia, studies have shown the correlation between virus pathogenesis with host immune responses and cytokine storm. Cytokine storm is potentially responsible for multi-organ damage due to the COVID-19 infection [6,98]. Data from China has shown that cardiac involvement is a common feature of hospitalized COVID-19 patients (20% to 30 %) and causes about 40% of deaths exclusively or related to respiratory failure [99]. It is suggested that similar to SARS-CoV and SARS-CoV-2 interferon-mediated responses, production of TNFα, and activation of TGF-β signaling associated with respiratory dysfunction and hypoxemia give rise to myocardial dysfunction in COVID-19 infection [100–101]. Arrhythmia is also reported as a common manifestation in patients; however, its pathophysiology is not still proven. Siripanthong B et al.’s study showed that arrhythmia is related to transferring a significant number of patients to the intensive care unit (ICU) [102].

Due to expressing a significant amount of ACE-2, which is considered
Table 1: Variants of SARS-CoV-2 based on three nomenclature methods, location and date of detection, and the location of mutations in the genome of the virus.

| GISAID clades | PANGO lineages | Nextstrain clades | Notable and elevated risk variants | WHO label | First detection | Mutations |
|---------------|----------------|------------------|-----------------------------------|-----------|----------------|-----------|
| **S**         | A.1–A.6        | 19B               | ‘reference sequence’ hCoV-19/Wuhan/WIV04/2019 (WIV04) |            |                |           |
| **L**         | B.3–B.7, B.9, B.10, B.13–B.16 | 19A               | Wuhan China                        |            |                |           |
| **O**         | V B.2          |                  | France South Korea                 |            |                |           |
| **G**         | B.1.5–B.1.72   | 20A               | Australia, western Europe          |            |                |           |
| **G**         | B.1.617.1      | Kappa (VOI)       | India                             | Oct 2020   | S:1452R, E484Q, D614G, P681R, E154K, Q1071H |           |
| **G**         | B.1.617.2      | Delta (VOC)       | India                             | Oct 2020   | S:452R, D614G, P681R, T19R, R1568G, T478K, D950N |           |
| **GH**        | CAL.20C        | Epsilon (VOI)     | United States [78], Southern California | October 2020 | S:S13, S:W152C, S:452R, ORF1a:4205V, ORF1b:3183Y |           |
| **B.1.3–B.1.66** | 21F              | Derived from 20A, 20G ("20C-US") | USA dominant in Wisconsin | Jan ’21 | S:S677H,R1443S, N:R688W, N:K417N, S:K467N, S:N501Y, S:E484K |           |
| **B.2**       | 20G/S:677P,Pelican | USA dominant in Louisiana | early 2021 | S:S677H, N:R688W, N:K417N |          |
| **21H**       | B.1.621        | Mu (VOI)          | Colombia                           | Jan 2021   | S:G484K, N:69S, N:K417N, S:K467N |           |
| **20H**       | (B.1.351)      | Beta (VOC)        | South Africa                       | Dec 2020   | S:S501Y, K417N, S:E484K, S:L18F, S:K417N |           |
| **GR**        | 20B            |                 | Nigeria                            | Mar 2020   | S:S501Y, E484K, S:D614G, S:K417N |           |
| **20 J**      | 20 J/S:501Y.V3 (B.1.1.28.1) (P.1) | Gamma (VOC) | Brazil, Japan | January 2021 | S:S501Y, E484K, S:D614G, S:K417N |           |
| **20D**       | 20B/S:484 K (P.2) | Zeta (VOI)         | Brazil                             | January 2021 | S:S484K, N:501Y, D614G, P681R, E1092K, H1101Y |           |
| **GR**        | 20B/S:265C (P.3) | Theta (VOI)       | Philippines                        | Jan 2021   | S:S484K, N:501Y, D614G, P681R, E1092K, H1101Y |           |

(continued on next page)
the main receptor of SARS-CoV-2 [103], in some cases, SARS-CoV-2 also affected the urogenital tract and testis and resulted in acute kidney injury (AKI) and testicle inflammation (Orchitis). It is proven that there is a positive correlation between ACE-2 mRNA and GFR and a negative correlation between ACE-2 mRNA and serum creatinine. However, the rate of patients showing renal injury caused by COVID-19 is relatively low. A study conducted on 116 COVID-19 patients showed no severe renal impairment in these patients [104].

The high expression of ACE-2 mRNA in infected patients has been reported in digestive organs (duodenum, colon, and small intestine), causing diarrhea and other gastrointestinal symptoms. In several studies, a significant increase in ACE2 mRNA expression has been reported in the gallbladder, testes, and kidneys [105]. Older children and even young adults might be affected by COVID-19, and may experience abdominal pain and diarrhea of unknown cause [106].

The interaction between ACE-2 and SARS-CoV-2 receptors leads to an elevation of free angiotensin II (Ang II) in serum. Consequently, Ang II accumulation can stimulate the release of inflammatory cytokines such as soluble IL-6, TNF-alpha, and IL-6 amplifiers, causing an increase in NFκB activation and eventually releasing the vast amounts of proinflammatory cytokines [107–108]. There is a correlation between pulmonary ACE-2 dysfunction and severe lung damage, thus it is suggested that the downregulation of virus-induced ACE-2 is important for COVID-19 infection pathology. ACE-2, as the renin-angiotensin system (RAS) regulator, cleaves the angiotensin II to produce the angiotensin 1–7 involved in anti-inflammation, anti-fibrosis, anti-thrombosis, and ROS neutralization [109]. The SARS virus S1 protein binding via the RBD domain to the ACE-2 receptor of host cells induces the cleavage of ACE-2 receptors by A disintegrin and metalloprotease 17 (ADAM-17). Therefore, the increased number of viruses and binding the spike to the ACE-2 receptor lower the ACE-2 level, and consequently decreased the conversion of angiotensin 2 to angiotensin 1–7. Elevated levels of angiotensin II eventually lead to vasoconstriction, muscle pain, lack of blood supply to tissues, inflammation, endothelial tissue damage, thrombosis,
and lung damage [110].

The decrease in ACE-2 function might intervene in RAS, leading to disturbance in the balance of fluid-electrolyte and blood pressure system and the inflammation increase in the respiratory system. Pro-inflammatory cytokines and chemokine’s such as IL-6, interferon gamma-induced protein 10 (IP-10), macrophage inflammatory protein 1α (MIP1α), MIP1β, and monocyte chemotactrant protein 1 (MCP1), recruit immune cells (T cells, macrophage, and monocyte) to the site of infection resulted in more production of IFNγ by T cells and promoted severe inflammation. Studies on the clinical features of COVID-19 have shown that ICU patients have higher plasma levels of pro-inflammatory cytokines, including IL-2, IL-6, IL-7, IL-10, granulocyte-colony stimulating factor (GCSF), CRP, IP10, MCP1, MIP1α, TNFα, and also have the lowest hyperactivated peripheral CD4 and CD8 T cells [111–114].

Although the increased expression of angiotensin-converting enzyme-2 (ACE-2) with increasing age has lung protective effect via restricting angiotensin-2 mediated pulmonary capillary leak and inflammation, severe COVID-19 infection in adults is correlated with the high level of ACE-2 and SARS-CoV-2 loads. The mild or asymptomatic infection in children may be due to several factors including, low levels of ACE-2 and TMPRSS2 receptor for SARS-CoV-2 in their respiratory tract [115–116], enhanced viral sensing, strong innate immune response, and high level of type I interferon (IFN) concentration in respiratory epithelial cells that fight the virus faster and more effectively compared to that of adults [117]. Children unlike adult patients do not exhibit severe infections due to dysfunctional over-active innate immune responses and repressed adaptive immunity. However, children with pre-existing illnesses are high-risk groups for COVID-19 infection [118]. Also, trained immunity in children due to routine live vaccines, including measles, mumps, rubella (MMR), polio, and BCG vaccination [119–122], and protective Th2 immunity by cytokines, including IL-4, IL-5, and IL-13 as well as the ability to reproduce the pulmonary epithelium can control COVID-19 infection at the site of virus entry [123] (Fig. 2). Studies showed that the incidence of COVID-19 cases in countries that routinely used the BCG vaccine in neonates was less than in countries where it is not used. This may be due to the enhancement of non-specific protection by heterologous lymphocyte activation and the initiation of innate immune memory [124] (Fig. 2).

Many patients have neurological symptoms, including dizziness, headache, vomiting, and delirium. Studies have shown that coronaviruses possess neurotropism, and can enter the CNS through different routes such as trans-synaptic pathways. Infected neurons related to the control of the cardio-respiratory system by coronaviruses in the brain stem may promote respiratory failure [125]. Mao et al.’s study has shown neurologic manifestations in 36.4% of patients [126]. Meanwhile, Garg RK et al. revealed that encephalopathy is common in COVID-19 patients older than 50 years old [127]. Additionally, disseminated intravascular coagulation, rhabdomyolysis, Testicle inflammation (Orchitis), and liver injury (high level of liver biomarkers ALT, AST) are the other identified manifestations induced by COVID-19 infection. Clinical neurological features, including encephalopathy, Cerebrovascular disease, Cerebral hemorrhage, have been reported in COVID-19 [128]. The use of some anticoagulation drugs can help us improve outcomes in severe patients [129]. Furthermore, in some cases of COVID-19, cutaneous manifestations are reported. However, more investigations are required to prove this relationship and the mechanism leading to this symptom [130].

5. Immune responses

5.1. Innate immune response

The innate immune system that is activated following virus replication by increasing the JAK-STAT signal pathway increases the expression of IFN-stimulated genes (ISGs) and reduces the spread of the virus by antigen-presenting macrophage. However, in most cases, the virus escapes the innate immune barrier due to the long incubation period and inhibition of interferon production by the N protein of SARS-CoV [108,131]. Studies also showed that dysregulated innate immune response is associated with lethal pneumonia in young COVID 19 patients [113]. However, a review study revealed that the adaptive immunity contributes to the control of SARS-CoV-2 in both mild and severe cases of COVID-19 [132].

Immune responses play a crucial role in CoVs disease severity [27]. In SARS-CoV-2, like two older CoVs, the increased level of inflammatory cytokines and chemokines in the first wave of infection is due to the accumulation of Natural Killer (NK) cells, as well as plasmacytoid (p) DCs, macrophages, CD4+ T cells, and NKT cells in the lungs and related to the emergence of cytokine release syndrome (CRS), followed by respiratory failure and ARDS in the hyper inflammation phase [133]. Furthermore, severely infected patients by beta coronaviruses showed an elevated concentration of serum C-reactive protein (CRP). IL-6 binds to the membrane-bound IL-6 receptor (mIL-6R) affects both acquired and innate immune systems (lymphocytes B and T, macrophages, neutrophils, and natural killer cells) via cis signaling, leading to CRS. On the other hand, in trans-signaling, IL-6 binds to the soluble form of IL-6R (sIL-6R) which can contribute to making cytokines storm including the release of IL-8, IL-6 and monocyte chemoattractant protein-1 (MCP-1), reduction of epithelial-cadherin expression on endothelial cells, and the release of vascular endothelial growth factor (VEGF), as a vascular permeability and ARDS mediators. The ample secretion of these factors eventually results in respiratory failure. Meanwhile, the third type of IL-6 signaling that was recently introduced as “trans-presentation” related to T helper 17 (Th17) cells may cause ARDS [134].

Like other viruses, CoVs have some strategies to escape from the host innate immune system to enter and infect target cells. By forming a double vesicle, CoVs can disturb the recognition of dsRNA by pattern recognition receptors (PRRs) [135]. Additionally, Nucleocapide, and accessory proteins encoded by ORF3b and ORF6 are responsible for blocking the IFN production cascade via several mechanisms [136–137]. These inhibitory functions promote viral replication and lead to disease severity at the initial stages of infection. CoVs also mimic the capping machinery of target cells via nsp14 and nsp16 in order to avoid immune system recognition [138]. Nsp3 also produces two functional proteins, macrodomain-x, and PLpro, involved in the immune system avoidance process [45,139–140].

5.2. Adaptive immune response

Adaptive immunity is mediated by activating T-dependent B cells by helper T cells, producing antibodies against the virus, and killing the virus by cytotoxic T cells [141]. The dysfunctional immune response can lead to lung injury by increasing immune cell accumulation in the lungs and producing pro-inflammatory cytokines [142,27,143]. Circulating cytokines can also damage other organs. Studies have demonstrated a strong correlation between neutralizing antibody (nAb) titers and disease severity and anti-spike IgG levels. COVID-19 ICU patients exhibited high nAb titers compared to milder symptoms or asymptomatic patients [144]. Furthermore, non-neutralizing antibodies promote the severity of the infection, and multi-organs damage via antibody-dependent enhancement (ADE) [139,145]. On the other hand, in a functional immune response through the attraction of virus-specific T cells, lung damage recovery and virus clearance could occur before spreading. In addition to this, neutralizing antibody activity causes efficient phagocytosis by resident macrophages. It is worth mentioning that the detection of IL-1β, which is significantly secreted during pyroptosis, an inflammatory type of programmed cell death, in COVID 19 patients is good evidence to show that SARS-CoV 2 induces pyroptosis in host cells similar to SARS-CoV and other cytopathic viruses [27,146].

A significant decrease in blood lymphocyte cells, which is considered as one of the main pathological features of COVID-19 infection is strongly related to clinical severity [147]. However, because of the
correlation between the decreased lymphocyte level (Lymphopenia) and the mortality rate in the 2009 H1N1 pandemic, we cannot identify lymphopenia as a specific key feature for COVID-19 infection [148]. Neutrophil/lymphocyte ratio elevation, which is remarkably common in COVID-19 patients (around 80%), may result from the migration of immune cells and the infiltration of lymphocytes into the respiratory system [27,149]. According to the current evidence-based studies conducted on MERS, SARS, and SARS-CoV-2, Th1 plays a crucial role in managing these infections, hence cellular immunity provided by T cells plays an essential role in gaining a successful vaccine [150–151]. Based on the previous studies on the coronavirus’s ability to infect monocytes, T cells, dendritic cells as well as the reduced ability of dendritic cells to control infection due to age-related changes, it is suggested that the novel SARS-CoV-2 may be able to infect dendritic cells [152]. There is a potential theory for understanding the immunopathogenesis of COVID-19, suggesting that dendritic cells may not be able to activate T lymphocytes, and it might cause the exhaustion and apoptosis of T cells. Although T cell response is impaired during SARS-CoV infection, coronavirus-specific memory T cells were found in recovered patients after two years [134,153]. In patients infected with SARS-CoV-2, impaired maturation of NK compartment or immigration of the mature circulating NK cells into peripheral tissues or the lungs have been reported. Furthermore, the NKG2A immune checkpoint is elevated on NK cells and CD8+ T cells from COVID-19 patients. NKG2A hinders cell cytoxicity via attaching to the non-classical HLA-E molecule [154]. Moreover, two studies indicated reduced frequencies of Treg cells in severe COVID-19 cases. Since Treg cells have been observed to clear ARDS inflammation in mouse models, a loss of Tregs might assist the progression of COVID-19 lung immunopathology. M2 macrophages (wound-healing) may be activated to repair inflamed tissues in ARDS but, Th2 shifting probably inhibits the wound-healing through secretion of inhibitory cytokine [155].

S1 receptor-binding domain (RBD), N-terminal domain (NTD), and S2 region are the major targets for the current developed neutralizing antibodies (nAbs) against SARS-CoV-2. It has been reported that some patients may not produce long-lasting antibodies against SARS-CoV-2. However, there is currently no conclusive evidence whether they will be re-infected or they will be at the recurrence risk of the original infection [156]. Studies have shown that despite some overlapped neutralizing epitopes among SARS-CoV-2 and other CoVs, SARS-CoV does not have a robust mechanism to inhibit antibody neutralization; mutations in SARS-CoV-2 S proteins during its spread may make it resistant to some monoclonal antibodies [157–158].

6. COVID-19 diagnostic tests

Clinical diagnosis of COVID-19 for the management of the current outbreak is mainly based on the combination of epidemiological history, clinical criteria along with RT-PCR assay, the sign of pneumonia on chest CT scan/X-ray and finally, detection of SARS-CoV-2-specific immunoglobulin IgM/IgG from patients’ sera by enzyme-linked immunosorbent assay (ELISA) [159–161].

6.1. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR)

Within five to six days of the onset of symptoms, the number of COVID-19 cases has demonstrated high viral loads in their upper and lower respiratory tracts [13,162]. A nasopharyngeal (NP) and oropharyngeal (OP) swabs are used to extract the SARS-CoV-2 RNA before both Real-time RT-PCR under the biosafety level 2 practices and proper use of personal protective equipment (PPE) condition [32,163–164]. For the late detection of severe COVID-19 patients during the intubation procedure, sputum sampling or bronchoalveolar lavage should be used because of the highest viral loads [165]. The preferred testing method is the Real-time RT-PCR test for two sequence regions N (as a screening) and ORF1b (as a confirmatory) that are highly conserved amongst sarbecoviruses (SARS-related coronaviruses) [166]. CDC has recommended two nucleocapsid protein targets (N1 and N2), and WHO has recommended the E gene for first-line screening followed by the RdRp gene as a confirmatory test due to the higher sensitivity and specificity [167]. Studies have shown that mutations in the N gene (C29200T) and E gene (C26340T) affect the SARS-CoV-2 detection [168–169]. Several factors have been recommended to describe the difference or the high false-negative rate (FNR) as high as 30% to 50% of Real-time RT-PCR testing. These factors include the number and site of primers, point mutation in the N gene, viral load in different anatomic sites of the patients, sampling methods, sample transport condition, and laboratory practice standard, which mostly contribute to high FNR [170].

Deep sequencing molecular methods such as next-generation sequencing and metagenomic next-generation sequencing will continue to determine future mutations of SARS-CoV-2, however, they are currently impracticable for diagnosing COVID-19 [171]. Meanwhile, some studies developed new methods to diagnose the SARS-CoV-2 virus RNA, such as loop-mediated isothermal amplification (LAMP) using a visual, colorimetric detection method [172] and Clustered regularly interspaced short palindromic repeats (CRISPR) technology [173–174].

6.2. Serological test

Serological methods have concentrated on detecting serum antibodies SARS-CoV-2 envelope spike (S) proteins (high sensitivity), and N protein (low sensitivity). Seroconversion usually happens after two weeks of symptom onset [175]. IgG tests work better than IgM and reveal better sensitivity when the samples are taken at least three months after the beginning of symptoms [176–177]. Yanan Wang et al. have shown that the positive results of virus-specific IgM were up to over 80% between 2 and 8 weeks after the onset of symptoms, then decreased quickly to under 30% in the third month. [177]. Generally, immunoassays for rapid detection of SARS-CoV-2 antibodies are used for lateral flow assays or population-level screening for detecting antibodies (IgM and IgG) against COVID-19. Serology detection is only utilized to determine the immune status of patients without symptoms and diagnose/confirm late COVID-19 cases or to assess the immunity of health care workers as the outbreak progress [166,178].

6.3. Hematological and inflammatory parameters

Assessment of the hematological laboratory data of COVID-19 positive patients showed that these patients had significantly higher levels of hematocrit (HCT) and mean platelets volume (MPV), and neutrophils (Neutrophilia) due to cytokine storm. These patients have significantly lower levels of Hemoglobin (Hb) [179] due to inhibition of erythropoietin production by cytokines [180]. Also, they have bone marrow’s incapability to engender adequate RBCs to transport oxygen. In addition, COVID-19 positive patients have Lymphopenia, eosinopenia, monocytes, and basophil because of the immune suppression, excessive inflammation, and immune-mediated apoptosis of lymphocytes [111,181]. Studies also showed that the levels of inflammatory parameters, including erythrocyte sedimentation rate (ESR) and CRP, D dimer, creatinine, and procalcitonin were significantly higher in severe COVID-19 patients compared to nonsevere patients [10,96,112].

6.4. Chest computed tomography (CT)

The positive load of Real-time RT-PCR reduces from the third week and finally becomes undetectable. Nonetheless, the Ct values of critical patients are lower than those of mild patients, and PCR positivity may continue for up to three weeks after the onset of the disease when most mild COVID-19 patients will yield negative results. However, a positive PCR result only shows the detection of viral RNA, which does not certainly show the presence of a viable virus [175]. Repeated testing
may be essential if patients have clinical symptoms of viral pneumonia and a history of exposure. Radiological findings, including chest computed tomography (CT) or magnetic resonance imaging (MRI) scan accordant with COVID-19 pneumonia [182]. For cases with a high clinical suspicion of COVID-19 infection with negative RT-PCR test results, a combination of repeated RT-PCR tests and chest CT scans can help clinicians to a rapid and accurate diagnosis [183]. Typical chest CT findings included two-sided pulmonary parenchymal ground-glass opacities (GGOs), consolidation, seldom with rounded morphology, and a peripheral distribution [184–187].

7. COVID-19 treatment strategies

However, with no specific medicine for COVID-19 patients up to now, there are several suggested potential therapies, including antiviral drugs, anti-inflammatory agents, convalescent plasma, Cellular therapy (Mesenchymal stem cell, DCS, and NK cells), Oxygen therapy, traditional herbal medicines, vitamins and micronutrients, and other options [188] (Table 2). The efficacy of these potential drug options has been investigated by researchers. As there is an urgent need for treatment due to the rapid outbreak of SARS-CoV-2, many scientists around the globe have launched clinical trials to find an efficient drug. In the case of co-infection, antibiotics and antifungals should be received by patients [79].

7.1. Anti-viral therapy

Human recombinant soluble ACE-2 (hrsACE-2) is a decoy biomolecule that, by neutralizing the virus, can inhibit SARS-CoV-2 from entering the host cells, decrease the viral load in early-stage of infection [189], and improves lung injury of COVID-19 patients [190]. Also, ATN-161 is a recombinant integrin-binding peptide that by interacting between the SARS-CoV-2 spike protein and α5β1 integrin and α5β1/ACE-2 inhibits the virus entry to host cells invivo [191] and potentially can inhibit SARS-CoV-2 entry as a therapeutic agent for COVID-19 infection [192].

According to previous studies, chloroquine and hydroxychloroquine used for malaria and also autoimmune diseases have shown some anti-viral activities in viruses such as dengue virus (DENV), West Nile virus (WNV), human immunodeficiency virus (HIV), Japanese encephalitis virus (JEV), and influenza virus [193–194]. Chloroquine and hydroxychloroquine can inhibit viral entry by blocking the proteolytic process and receptor glycosylation. The results of in vitro studies on these drugs are auspicious. There is no evidence about the efficacy of chloroquine for SARS and MERS treatment [195]. However, it is suggested that chloroquine can inhibit virus fusion, replication, assembly, release, and other crucial processes through the change of cell surface pH [188,196–197]. Some studies proposed the combination therapy of hydroxychloroquine with azithromycin to control the cytokine storm in COVID-19 patients [198] and the Food and drug administration (FDA) suggested emergency use of chloroquine and hydroxychloroquine over a period of time to decline symptoms in infected COVID-19 patients, however, after a while, studies did not show efficiency against COVID-19, it revoked the law declaring that their risks outweigh the benefits [199] (Table 2).

Lopinavir/ritonavir is a combination of protease inhibitors used in HIV treatment and thought to be a potential COVID-19 infection therapy [200]. However, Lim J et al.’s case study showed that using the LPV/RTV reduced the clinical symptoms of COVID-19 infection [201]. There were no significant differences between patients who received standard care and the others who received lopinavir/ritonavir [202–203]. Andrea Giacomelli et al.’s study revealed that early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection [204] (Table 2).

Ribavirin is an antiviral medication that, together with IFN-α is used to treat RSV, HCV, and some viral hemorrhagic fevers [205]. Studies have shown that the combination of ribavirin and interferon would stop the polymerase activity; however, their significant adverse effects seem to be a barrier to their prescription [206–207]. Remdesivir is a nucleoside analog that intervenes with RNA-dependent RNA polymerase (RdRp), resulting in the inhibition of viral replication [208]. The FDA approves Remdesivir for COVID-19 treatment. Many studies have shown that Remdesivir can reduce the recovery time of hospitalized patients with COVID-19 [209–210] and is suitable for viral prophylaxis and in the early stages of virus replication, However, it is needed to monitor renal and liver function in patients [211–212] (Table 2). On 20 November, WHO released a conditional recommendation against the use of remdesivir in hospitalized COVID-19 patients and announced that there is no evidence that remdesivir can improve survival and other outcomes in hospitalized COVID-19 patients [213]. Studies have shown that using remdesivir is not associated with clinical benefits, and does not result in a substantial increase in adverse effects [214–216].

7.2. Anti-inflammatory agents

Since cytokine storm is a critical feature of exacerbation of COVID-19 infection and consequently ARDS, immunomodulators, and cytokine antagonists, have been considered a potential treatment [98]. In September 2020, WHO recommended the use of interleukin-6 inhibitors and Corticosteroids that may have important benefits in severe COVID-19 patients [219–220]. Researchers found that the use of tocilizumab and Sarilumab, recombinant humanized anti-human -interleukin-6 receptor monoclonal antibodies (IL-6R Ab), has significantly improved therapeutic effects on patients who experienced cytokine storm during COVID-19 infection [221]. Tocilizumab can bind to the IL-6 receptor with high affinity, thus preventing IL-6 itself from binding to its receptor, rendering it incapable of immune damage to target cells, and alleviating the inflammatory responses [222]. Although several studies have shown that Tocilizumab does not prevent death in acute patients, TCZ appears to be an effective treatment option in COVID-19 patients with a risk of cytokine storms. [223–225]. Recent studies have shown that dexamethasone, a glucocorticoid hormone that is produced in the adrenal cortex and acts as an anti-inflammatory drug has a promising result in treating severe cases of COVID-19 [226]. Only low doses of this drug are prescribed to patients admitted to the ICU in a severe condition requiring oxygen, which can be life-saving for this group of patients and not for patients who do not require respiratory support [227–229]. Dexamethasone by binding to glucocorticoid receptor (GR) on the cell membrane and traveling to the nucleus via binding to specific sites of DNA inhibits the transcription of pro-inflammatory cytokines such as IL-1, IL-2, IL-6, IL-8, TNF, IFN-Y and activation of anti-inflammatory cytokine genes such as IL-10 [230–231]. Glucocorticoids based on their concentration in the blood could have both stimulatory and inhibitory effects on the immune response [232].

Dexamethasone has more and quick antiinflammatory effects to control the cytokine storm-mediated damage of COVID-19 patient lung tissue, compared to other corticosteroids, including hydrocortisone, prednisone, or methylprednisolone [233]. Some studies however showed that Low dose and Short-course methylprednisolone effectively improved the prognosis of patients with severe COVID-19 pneumonia if used before the onset of ARDS [234]. A study showed that the use of systemic glucocorticoids did not reduce mortality and prolonged the duration of hospitalization of non-severe but advanced COVID-19 patients [235]. Also, since studies determined that the complement complex is associated with SARS-CoV-2 pathogenesis [236], complement pathway inhibitors, including C5 and C3 inhibitors, could be an attractive therapeutic approach for the treatment of COVID-19 [237]. Meanwhile, Antiplatelets by platelet activation reducing or nuclear factor-kB (NF-kB) attenuation could have decreased inflammatory response and virus propagation [238] (Table 2).

Type 1 interferons (IFN-I) are a subgroup of interferon proteins, including IFN-α (alpha), IFN-β (beta), etc., secreted by various cell types,
Summary of the proposed therapeutic approaches under investigation for COVID-19.

| Therapy strategies        | Treatment                                      | Procedure and effectiveness of the drug                                                                 | Reference |
|---------------------------|------------------------------------------------|----------------------------------------------------------------------------------------------------------|-----------|
| Viral entry inhibitor     | Umifenovir (Arbidol)                           | An antiviral drug for treating SARS-CoV-2 by blocking trimerization of the spike glycoprotein and inhibiting host cell attachment. | [268–269]|
|                           | Nafamostat                                     | An active synthetic serine protease inhibitor against TPRRS2 and suppresses TPRRS2-dependent host cell entry. | [270–271]|
|                           | Mesylate (Futhan)                              |                                                                                                          |           |
|                           | HrsACE-2                                       | HrsACE-2 inhibits SARS-CoV-2 from entering the host cells.                                               | [189–190]|
|                           | ATN-161                                        | ATN-161 is an integrin-binding peptide that, by interacting between the SARS-CoV-2 spike protein and sP1 integrin inhibits the virus entry to host cells. | [191–192]|
| Anti-viral therapy        | Interferons:                                   |                                                                                                          |           |
|                           | Interferon-alpha (IFNα) and Beta (IFNβ)        | Although the early administration of interferon can reduce viral load and improve COVID-19 symptoms, interferon therapy has not shown any significant benefits in the late phase. Although it has some adverse effects if administered later. The combination of ribavirin and interferon can stop the polymerase activity. | [98,171,206]|
|                           | Protease inhibitors (Lopinavir/ritonavir)       | These drugs, which are used as HIV protease inhibitors, can be a potential treatment for COVID-19 infection, and some studies have shown that the use of these drugs has no significant effect. | [200,272]|
|                           | Chloroquine and hydroxychloroquine             | Although chloroquine and its derivatives are used to treat malaria, autoimmune diseases and some viral infections, and can inhibit endosomal/lysosomal trafficking, maturation of virus fusion protein, studies have shown that they are ineffective against COVID-19 and due to cardiovascular toxicity and other safety concerns, the risks are not considered to be beneficial. Remdesivir is a nucleoside analog that, by intervention with viral RdRp, inhibits viral replication. Remdesivir is an FDA-approved antiviral drug and globally used for COVID-19 treatment in the early of infection which decreases recovery time for patients hospitalized with COVID-19. Highly conserved genes of SARS-CoV-2, including mP5, RdRP, and N protein, can be a potential target of siRNA for COVID-19 treatment. | [193–195,199]|
|                           | RNA synthesis inhibitor (Remdesivir)           | Bioinformatics data showed that several miRNAs could have antiviral properties by targeting the ORF1ab and the 5' genes. Studies showed that miR-200c and miR-98-5p have antiviral activity by inhibiting the ACE-2 and TPRRS2 miRNAs, respectively. Also, miR-155, an inflammation-associated miRNA, is overexpressed in SARS-CoV-2 infected cell lines, and elimination of this miRNA may decrease pulmonary injuries of COVID-19 infection. | [208–210]|
| RNA Interference (RNA)    | siRNA and miRNA                                | The siRNA and miRNA targeted highly conserved genes of SARS-CoV-2, including nsp5, RdRP, and N protein, can be a potential treatment for COVID-19. |           |
|                           | Glucocorticoids (Dexamethasone)                | Glucocorticoids may modulate inflammation-mediated lung injury and reduce. Low doses of Dexamethasone reduced 28-day mortality in the presence of receiving respiratory support, also may benefit in presence of chronic obstructive pulmonary disease (COPD), septic shock, or ARDS. | [227–229]|
|                           | Corticosteroids (Methylprednisolone)           | Some studies showed that low doses of methylprednisolone effectively improved the prognosis of patients with severe COVID-19 pneumonia if used before the onset of ARDS. | [234–235]|
|                           | Cytokine inhibitors (Tocilizumab)              | Tocilizumab and Sarilumab are recombinant- monoclonal antibodies against the IL-6 receptor. Although several studies have shown that Tocilizumab does not prevent death in acute patients, TCZ appears to be an effective treatment option in COVID-19 patients with a risk of cytokine storms. interleukin-6 inhibitors may provide important benefits in patients with severe COVID-19 | [224,277]|
|                           | TNF-α inhibitors (Infliximab)                  | Seven-day administration of infliximab has successfully treated inflammatory bowel disease (IBD) patients with active disease and COVID-19 pneumonia. | [278–279]|
| Anti-inflammatory agents  | Complement inhibitors (Eculizumab)             | Eculizumab is a humanized monoclonal antibody functioning as a terminal complement C5 inhibitor. A case study showed that C5 inhibition holds potential as a novel anti-inflammatory therapy in COVID-19. | [280–282]|
|                           | C5 inhibitors (Eculizumab)                    |                                                                                                          |           |
|                           | C3 inhibitors (AMY-101)                        |                                                                                                          |           |
|                           | Antiplatelets:                                 | Aspirin and Clopidogrel reduce platelet activation, and Ticagrel and Prasugrel by nuclear factor-kB (NF-kB) attenuation decrease inflammatory response and virus propagation. | [238]|
|                           | Aspirin and Clopidogrel                        |                                                                                                          |           |
|                           | Ticagrel and Prasugrel                         |                                                                                                          |           |
|                           | Anticoagulants:                                | Heparin, by blocking the viral S protein, inhibits virus attachment and Si-S2 cleavage. Also, it acts as an anti-inflammatory, anticoagulant, and venous thromboembolism (VTE) prophylaxis agent. | [238]|
|                           | Heparin                                        |                                                                                                          |           |
|                           | Vitamin K Antagonists                          |                                                                                                          |           |
|                           | Dagabatran, Apixaban, Rivaroxaban, Edoxaban   |                                                                                                          |           |
|                           | Convalescent plasma therapy                    | Transfusion of convalescent plasma with higher antibody titers to SARS-CoV-2 compared with lower antibody titers within three days of their COVID-19 diagnosis, as strategies to improve cytokine storm symptoms, significantly reduced the mortality in hospitalized COVID-19 patients. | [98,260,283–284]|
| Immunotherapy             | Mesenchymal stem cell treatment                | Mesenchymal Stem Cells (MSC) have immune-regulatory and anti-inflammatory activities. They can promote the differentiation of abnormal T cells and macrophages into regulatory cells (Treg) and anti-inflammatory macrophages, and inhibit pro-inflammatory cytokine production and repair the damaged tissues in severe COVID-19 pneumonia patients, particularly for the patients in critically severe conditions. | [285–287]|
|                           | Dendritic cell (DC) and monocyte-based therapy| In this method, after collecting the PBMCs from vulnerable patients and isolating monocytes from PBMCs, monocyte-DCs are pulsed with SARS-CoV-2 peptides. Then isolated autologous T cells are stimulated and are primed with pulsed monocyte-DCs, and eventually, these personalized T cells are infused into the populations as prevention or treatment against COVID-19. DC-based therapy is a potential treatment for COVID-19 ARDS. | [245–246]|
|                           | Natural killer cells (NK),                    |                                                                                                          | [242–244]|

(continued on next page)
including endothelial cells, dendritic cells, fibroblasts, macrophages, lymphocytes, and others, during the recognition of viral components by pattern recognition receptors (PRR). IFN-I, by stimulating the interferon-stimulated genes (ISG) in macrophages and NK cells, elicit an anti-viral immunity in the early stage of infection in patients with mild interferon-stimulated genes (ISG) in macrophages and NK cells, eliciting an anti-viral immunity in the early stage of infection in patients with mild COVID-19, patients. interferon therapy has not shown any notable effects if administered later [98,171] (Table 2).

Coronaviruses potently suppress type I IFN responses [241]. Since NK cells as cytotoxic lymphocytes are a crucial component of the innate immune system and are critical in response to many viral infections [242], the reduction of circulating NK cells in the primary infection in high-risk individuals as well as more recrui NK cells to the lungs, are observed in hyper inflammation phase these cells may be responsible for the progression and severity of COVID-19 [242-243]. Studies have shown that the use of umbilical cord blood-derived or isolated NK cell from healthy donor PBMCs may be helpful to the treatment of COVID-19 in the early of infection. Meanwhile, the activation of pathogen recognition receptors, including toll-like receptors 2, 6, and 9 (TLR2/6/9) by PUL-042 CpG oligodeoxyribonucleotides (CpG ODNs) in the early stage of COVID-19 infection, particularly on DCs and B cells, leading to innate immune stimulation can be employed as prophylactic or therapeutic [244]. In the hyperinflammation level of COVID-19 infection in vulnerable patients in which the host immune system remains active over a prolonged period, the inhibition of TLR and NK cell pathway can help to prevent or dampen hyperinflammation and multi-organ complications [244] (Table 2).

7.3. Cellular therapy

Dendritic cells (DCs) and macrophages have a crucial role in innate immunity and produce inflammatory cytokines and chemokines. DC-based therapy is a potential treatment for COVID-19 ARDS. At first, in this method, after collecting the PBMCs from vulnerable patients and isolating the monocytes, monocyte-DCs are pulsed with SARS-CoV-2 peptides. Then the isolated autologous T cells are stimulated and primed by pulsed mononuclear-DCs. Eventually, these personalized T cells are infused into the populations as a prophylactic or therapy of COVID-19 infection [245-246] (Table 2).

Interestingly, several studies have stated that Mesenchymal Stem Cells (MSC) are isolated from a different tissue, including peripheral blood, umbilical cord blood (hUC-MSCs) [247], bone marrow (BM-MSCs) [248], and adipose tissues (AT-MSCs) [249] have immune-regulatory and anti-inflammatory activities and are safe and effective for the treatment of COVID-19 pneumonia patients, especially in patients with ARDS. They can stimulate the differentiation of abnormal T cells and macrophage into T regulatory cells (Treg) and anti-inflammatory macrophages, as well as inhibiting pro-inflammatory cytokine production, thereby improving lung injury and ARDS and enhancing tissue repair and reducing lung fibrosis of patients [250-252] (Table 2).

7.4. Immunotherapy

Human antibodies in convalescent plasma block the virus entry into the target cells by inhibiting the spike protein binding to ACE-2 and thus limits viral amplification [253-254]. FDA issued an Emergency Use Authorization (EUA) for convalescent plasma to treat COVID-19 [255], and some studies suggested a benefit of high-titer plasma in hospitalized patients with COVID-19 in the early stage of infection (within three days of their COVID-19 diagnosis) [256-259]. However, some studies demonstrated no difference in seven-day mortality between the patients who received high-titer and those who received low-titer plasma and showed that the data are insufficient to recommend the convalescent plasma for COVID-19 treatment [255]. Also, plasma exchange and blood filtration are considered as strategies to improve cytokine storm symptoms [98,260] (Table 2).

7.5. RNA interference (RNAi)

RNA interference process (RNAi) involves endogenous (originating in the many eukaryote cells) or exogenous (viral or recombinant) RNA molecules that either destroy the target mRNA or inhibit its translation. Small interfering RNA (siRNA) is a 20–25 base pairs in length double-
stranded non-coding RNA molecules, which can regulate the expression of genes by RNA interference (RNAi) phenomenon [261]. Studies showed that among SARS-CoV-2 genes, nsp5 sequence encoding 3CLpro and RdRP, the key enzyme for replicating the virus, and N protein genes, are highly conserved that have been determined as a potential target of siRNA for COVID-19 treatment [262–264] (Table 2).

The miRNAs are a group of small non-coding RNAs with twenty-two nucleotides of length that are transcribed from the nucleus genome and play a significant role in regulating the eukaryotic gene. miRNA can be used as a therapeutic agent for the COVID-19 treatment. Khan et al.’s bioinformatics study showed that several miRNAs could have antiviral properties by targeting the ORF1ab and the S genes. Other studies have shown that miR-200c by inhibiting ACE-2 mRNA [265] and miR-98-5p by regulating TMPRSS2 [266] have antiviral activity. Also, Wyler et al.’s study showed that among the small RNA profiling in SARS-CoV-2 infected cell lines, the inflammation-associated miR-155 was strongly overexpressed, and elimination of this miRNA could reduce the pulmonary injuries of COVID-19 patients [267] (Table 2).

7.6. Vitamins and micronutrients

It is suggested that the deficiency in some vitamins and micronutrients such as vitamins B, C, D, and zinc may reduce the function of the immune system. Furthermore, losing significant weight could impact the severity of infection, the number of hospitalization days, and response to therapy. For these reasons, improving the nutrition and diet patterns could effectively strengthen the immune system and reduce the side effects induced by infection [303].

Due to the improving of the innate and specific immune system and decreasing pro-inflammatory cytokines, Vitamin B could potentially be used to prophylaxis and treat SARS-CoV-2 infection [297–298]. The rapid release of vast amounts of cytokines and free radicals increases oxidative stress during ARDS and, consequently, multi-organ damage and death. Thus, high doses of an antioxidant such as vitamin C could be considered as a protection and a treatment against COVID-19 [304]. Like many other micronutrients, Vitamin D has an immunomodulatory function and can potentially inhibit the release of inflammatory cytokines during infection [299]. Severe vitamin D deficiency (<25 nmol/L) is associated with disease progression and increased mortality in older, housebound individuals COVID-19 patients [305–307]. The assessment of 25 randomized control trials revealed that vitamin D has a protective impact against respiratory infections [303]. A Meta-analysis study reported that regular uptake of vitamin D could reduce the risk of acute respiratory infection and the severity of diseases induced by SARS-COV-2 [300]. Although Hastie et al. reported that no significant association was found between 25 (OH) D and the risk of COVID-19 infection, and vitamin D seems not to be an effective option to improve the patients’ condition [308]. Copper (Cu) can potentially boost the innate and adaptive immune system against viral infection by involving natural killer cells, macrophages, B cells, and T helper cells. Cu can kill many types of viruses, such as poliovirus and human immunodeficiency virus type 1 (HIV-1) [301]. Lactoferrin (LF), which is found in mammalian milk, has shown antiviral activity. Binding to HSPGs in the host cell surface, LF inhibited murine coronavirus and Hcov-NL63 from entering into the host cells. LF also has anti-inflammatory and immunomodulatory activities, which can be potentially helpful in alleviating the symptoms of COVID 19 infection [296].

Impaired glucose metabolism in obese patients, and type 2 diabetes, as well as hypertension as in most other diseases are the important risk factors for COVID-19 [309]. It seems that consuming a healthy diet with more fibers, vegetables, antioxidant grains, and unsaturated fats along with taking vitamin supplements can significantly improve the prevention and recovery process of many types of disease, including COVID-19 [310–312].

8. Vaccine development against SARS-CoV-2

Typically, a vaccine takes eight to ten years to develop [313]. The optimistic timeline for developing the COVID-19 vaccine in the body was estimated at least 12 to 18 months [314]. Vaccines have to pass several trial phases to ensure that they are efficient and safe. The development of a vaccine for human use is in processes that comply with current Good Manufacturing Practice (cGMP) to ensure vaccines’ consistent quality and safety. Once sufficient preclinical in vitro and in vivo testing data are available and initial batches of the vaccine have been produced by Current Good Manufacturing Practices (cGMP) quality, clinical trials might be initiated. Typically, clinical development of vaccine candidates begins with a small number (20–80) in phase I trials, followed by phase II trials on a large number of volunteers (100–300) to determine the initial proof of vaccine formulation efficacy and dose, and finally the efficacy and quality of a vaccine requiring a proven evaluation in a broader cohort phase III trials on many people (1000–3000). If efficiency is confirmed, a vaccine might be fully licensed or approved for emergency use by regulatory agencies. Vaccines then enter phase four of Clinical Trial for Post-Market Surveillance and adverse events reporting as long as they are on the market. Urgently respond to epidemics based on developing the vaccine technology can differ. For example, since the technology of H1N1 influenza vaccine was previously well developed in eggs and cell-based platforms, the influenza vaccine relatively developed rapidly. However, in the case of previous SARS coronavirus, there has been an experience designing a vaccine for SARS in 2003 using protein S, and a number of vaccines such as mRNA flu vaccines by Moderna (mRNA-1010) and Pfizer/BioNTech [315] have entered the human clinical phase that rapidly contributed to the development of COVID-19 vaccines [44,316].

As of the 5th of September 2020, the global COVID-19 vaccine R & D landscape includes 206 vaccine candidates, of which; eight approved for full use and entered into phase four, seven were authorized in early or limited use, 53 candidate vaccines are in the clinical phase 1, and 45 candidate vaccines are in phase 2 evaluation on humans, 33 candidate vaccines are at the final stages of testing (phase 3) and more than 75 vaccines are in preclinical evaluation (Table 3) [25–26].

The SARS-CoV-2 spike (S) glycoprotein is a central focus in vaccine development. S protein contains amino-terminal S1 as an RBD and carboxyl-terminal S2 as membrane fusion and induction of neutralizing (VN) antibodies that can inhibit binding to the host receptor [160]. Other SARS-CoV proteins, including M protein and N protein, can also induce VN antibodies and contain T-cell epitopes, respectively that may also be vaccine targets [317–318].

Different types of SARS-CoV-2 Vaccines under development, include live attenuated vaccines, Inactivated vaccines, recombinant viral vector vaccines, recombinant viral proteins (Subunit Protein and virus-like particle vaccines), and nucleic acid vaccines (mRNA or Plasmid). Live attenuated vaccines contain weakened whole viruses by a temperature-sensitive mutant with restricted replication to the upper respiratory tract and reverse genetics to construct additional targeted attenuating mutations, to create a protective immune response, but cannot cause illness in healthy people. However, although live attenuated vaccines have a strong and lasting immune response, they are not suitable for people with immune deficiency since the phenotypic or genotypic reversion is possible [316]. COVI-VAC is an Indian live attenuated vaccine against SARS-CoV-2 in which virus genes have been rewritten with hundreds of mutations (Table 3) [319].

Meissa intranasal COVID-19 Vaccine (MV-014–212) is a recombinant live attenuated human respiratory syncytial virus (BSV) that expresses a chimeric SARS-CoV-2 spike protein (composed of ectodomain and transmembrane domains of SARS-CoV-2 spike, and the cytoplasmic tail of the BSV fusion protein) and can stimulate both mucosal (nasal IgA) and systemic (IgG) antibodies against SARS-CoV-2. In addition to preventing infection, this vaccine, unlike other vaccines can block the transmission of the virus and provides a long-lasting immunity against
Table 3
Summary of the Clinical-phase COVID-19 vaccine candidates.

| Platform                  | target                | Vaccine name                        | Vaccine characteristics                                                                 | Efficacy/Dose/routes of administration/storage | stage of clinical evaluation/regulatory status                                                                 | Reference |
|---------------------------|-----------------------|-------------------------------------|----------------------------------------------------------------------------------------|-----------------------------------------------|---------------------------------------------------------------------------------------------------------------|-----------|
| Inactivated vaccines      | Whole virion          | WIBP-CorV                           | Inactivated SARS-CoV-2 Vaccine. Developed by the Wuhan Institute of Biological Products. | 72.51% efficacy                               | Phase 1/2 were designed by Wuhan Institute of Biological Products/Sinopharm (ChiCTR2000031809). Phase 3 trials are undergoing in several countries. China approved the Wuhan vaccine for general use. Limited used in the United Arab Emirates. | [355]     |
|                           | BBIBP-CorV            | BBIBP-CorV                          | Inactivated SARS-CoV-2 Vaccine. Developed by Beijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm). | 79.34% efficacy/2 doses, 3 weeks apart/Muscle injection/Refrigerated | Phases 1/2 by Beijing Institute of Biological Products/Sinopharm (ChiCTR2000032459). Phase 3 trial began in the United Arab Emirates in July, and in Morocco and Peru the following month (ChiCTR2000034780). Approved in China, Bahrain and the United Arab Emirates. Authorized for emergency use in several other countries. Accepted by WHO for Emergency Use Listing (EUL). Entered Phase four Clinical Trial | [356–358] |
|                           | CoronaVac, known as FiCoVacc | BBV152 is an inactivated SARS-CoV-2 Vaccine. Developed by Sinovac Biotech in China. | 78% efficacy, Efficacy against Severe COVID-19 disease is 100% injection into the deltoid muscle/2 doses, 4 weeks apart/Storage at least a week at room temperature | Phases 1/2 by Sinovac Biotech (NCT04383574) (NCT04352608). Phase 3 trial (NCT04617483). Phase 3 trial in Turkey (NCT04582344), Indonesia (NCT04508075) and Brazil (NCT04456595). Approved in China and authorized for emergency use in several other countries. Accepted by WHO for Emergency Use Listing (EUL). Entering Phase four Clinical Trial | [359–360] |
|                           | BCG vaccine           | BCG-CORONA                          | Live attenuated vaccine against respiratory syncytial virus (RSV) that expresses the spike (S) protein of SARS-CoV-2. Developed by Meissa Vaccines company | One dose (0.1 ml) of the licensed BCG vaccine. | Phases 1/2 trials induce tolerable safety outcomes and enhanced immune responses (NCT04471519). Authorized for emergency use in India and several other countries. Expression of interest (EOI) data submitted to WHO on 19 April for EUL. | [361–362] |

(continued on next page)
### Table 3 (continued)

| Platform                        | target | Vaccine name          | Vaccine characteristics                                                                 | Efficacy/Dose/routes of administration/storage                  | stage of clinical evaluation/regulatory status | Reference                  |
|---------------------------------|--------|-----------------------|----------------------------------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------|------------------------------|
| Recombinant viral proteins S    | protein| Novavax               | NVX-CoV2373 is a Sabin Protein vaccine, including a full-length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvant with Matrix M1. Developed by Novavax company in the USA. | 96% efficacy against original coronavirus, 86% against B.1.1.7, and 49% against B.1.351. 2 doses, 3 weeks apart/Muscle injection/Stable in refrigerator. | US (NCT04632537), Egypt (NCT0350931), Netherlands (NCT04328411), and South Africa (NCT04379936). Phases 1/2 were generally well-tolerated and elicited robust antibody responses (NCT04533999). Phases 1/2 by the biOtech company (NCT04368988). phase 3 trial in the US and Mexico (NCT04611802). phase 3 trial in the UK (NCT04583995). Accepted by WHO for EUL. Entering Phase four Clinical Trial. | [366–367]                     |
| EpiVacCorona                    |        |                       | Vaccine name for blocking the spike 1 protein receptor-binding domain (S1-RBD) of SARS CoV-2. Developed by Federal Budgetary Research Institution State Research Center of Virology and Biotechnology in Russia. | 2 doses (0.5 ml 2) 3 weeks apart/Muscle injection/Stable in refrigerator for up to two years. | Phase 1 trial (NCT04445194) and Phase 2 (NCT04466085), (NCT04550351). Phase 3 trial (NCT04833101). Phase 4 trials designed in China. Emergency used in China and Uzbekistan. | [368]                       |
| ZF2001                          |        |                       | Recombinant peptide vaccine for RBD section of the spike protein of SARS CoV-2. Developed by China’s Anhui Zhifei Longcom Biopharmaceutical and the Institute of Microbiology of the Chinese Academy of Sciences. | 3 doses, 4 weeks apart/Muscle injection | Phase 1 (NCT04445194) and Phase 2 (NCT04466085), (NCT04550351). Phase 3 trial (NCT04833101). Phase 4 trials designed in China. Emergency used in China and Uzbekistan. | [369]                       |
| CoVLP                           |        |                       | Plant-based COVID-19 vaccine in combination with adjuvants (AS03 or CpG1018) to boost the immune system’s response to the viral proteins. Virus genes delivers into leaves, and the plant cells (called Nicotiana benthamiana,) then create protein shells that mimic viruses. Developed by Medicago in Canada. | 2 doses, 3 weeks apart/Muscle injection/Stable in refrigerator. | In phase 1 two doses of CoVLP (3.75 μg + AS03), lead to strong humoral and cellular responses (NCT04450004). Phase 2/3 started on November 19, 2020 (NCT04636697). | [370]                       |
| COVID-19 VLP-based vaccine       |        |                       | Virus-like particle, based on RBD displayed on virus-like particles. | Phases 1/2 trial in the Netherlands (NCT04313127) and Phase 3 trial (NCT04540419). Phase 3 and produced in China. Emergency use in other countries. | Pre-Clinical in Switzerland by Salva GmbH. The vaccine was able to induce high levels of antibodies within a week in test animals. | [371]                       |
| Recombinant viral vectors S      | protein| Canary, Covidecia also known as Ad5-nCoV | Non-Replicating Viral Vector (Ad5-nCoV) is based on their adenovirus type 5 vector platform (deletions in the E1 and E3 early genes) expresses the full-length spike glycoprotein. Developed by Canary Biologics company. | 65.28% efficacy/Single-dose/Muscle injection/Refrigerated. | Phase 1 in Wuhan, Hubei, China (NCT04833101). Phase ii trial (NCT04341389). phase III trial (NCT04540419) Phase 3 by Canary Biologics in China. Approved in China. | [372–374]                     |
| COVID-19 Vaccine Janssen (JNJ- 78436735; Ad26. COV2.S) |        |                       | Based on the human adenovirus Ad26 expresses the full-length spike protein. Developed by Johnson & Johnson in the Netherlands and the US. | 72% in the United States, 68% in Brazil, and 64% in South Africa. 1 dose/Muscle injection/Storage up to two years frozen at −4 °C (-20 °C), and up to three months refrigerated at 36–46 °F (2–8 °C). | Authorized for emergency use in the United States, the European Union, Canada, and other countries. WHO’s accepted for EUL. Enter Phase four Clinical Trial phase 1/2 trials in the US (NCT04436627) and Japan (NCT04509947). phase 3 trials (NCT04505722) and (NCT04614948). Authorized for emergency use in the United States, the European Union, Canada, and other countries. | [343]                       |
| Sputnik V or Gam-Covid-Vac       |        |                       | Sputnik V is a combination of two different adenoviruses, Ad26 and Ad5. Developed by Gamaleya Institute, in Russia. The vaccine is early use in Russia. | 91.6% efficacy 2 doses with 3 weeks apart/muscle injection/Freezer storage. | Enter Phase four Clinical Trial phase 1 trial (NCT04436471) phase 2 trial (NCT04437875). Phase 3 trials at 25 hospitals and polyclinics in Moscow, Russia on Sept 7 and Nov 24, 2020, (NCT04583996). | [341,375–376]                |

(continued on next page)
| Platform | target | Vaccine name | Vaccine characteristics | Efficacy/Dose/routes of administration/storage | stage of clinical evaluation/regulatory status | Reference |
|----------|--------|--------------|-------------------------|-----------------------------------------------|---------------------------------------------|-----------|
| AstraZeneca (AZD1222) also known as Vaxzevria and Covishield in India | | Comirnaty | mRNA vaccine incorporating the S protein of SARS-CoV-2, developing immune responses against S protein | 95% efficacy in Phase 3 trial; Muscle injection/storage at 2 doses, through muscle injection/storage at -20 °C | WHO’s Emergency Use Listing (EUL) | [377–378] |
| | | Spikevax, (mRNA-1273, Moderna Biotech) | mRNA-1273 vaccine is a part of the spike protein genetic code embedded in special lipid-based nanoparticles. | More than 90% efficacy/2 doses, through muscle injection/storage at 30 days with refrigeration, 6 months at -20 °C | Phase 1/2 trial (NCT04283461) | [385] |
| | | INO-4800 DNA | DNA vaccine candidate that contains the plasmid pOX9501, which encodes for the entire length of the Spike glycoprotein of SARS-CoV-2. | 2 doses (1.0 mg)/Administered intradermally by Electroporation/stable at room temperature for more | WHO’s accepted for Emergency Use Listing (EUL) | [338,386–388] |
| | | LV-SMENP-DC | LV-SMEN-DC is a dendritic cells (DCs) modified with a lentiviral vector expressing synthetic minigene SMENP and immune-modulatory genes to modify DCs and to activate CTLs by LV-DC presenting SARS-CoV-2 specific antigens. | 76% in a U.S. study/2 doses/3 weeks interval | Phase 1/2 clinical trials in South Africa (NCT04324406) | [379] |
| | | Covid-19/aAPC vaccine | Pathogen-specific aAPC (artificial antigen-presenting cell), modified with a lentiviral vector expressing synthetic minigene based on multiple viral genes to express the viral proteins and immune-modulatory genes to modify the aAPC and to activate T cells | Phase 1 by Shenzhen Geno-Immune Medical Institute, in China (NCT04299724) | [380] |
| | | Coroflu | Coroflu, a Non-Replicating Influenza virus Vector based on FluGen’s flu vaccine candidate known as M2SR (lacks the M2 gene), is a self-limiting version of the influenza virus, which is modified by insertion of the SARS-CoV-2 gene sequence of the spike protein. Coroflu also expresses the influenza virus hemagglutinin protein antigen and gets immune responses to both coronavirus and influenza. | intra-nasal delivery | Pre-clinical development | [381] |

Notes: Sputnik Light is a one-dose version of the Gamaleya vaccine that is now authorized in Russia.
Virus-like particles (VLPs) are self-assembled viral protein complexes that can enhance the vaccine’s safety and efficacy [46]. S protein or RBD subunit vaccines as well as VLP vaccines are highly safe and can induce high cellular and humoral immune responses, possibly present in 90.3%, and 86.3%, respectively [323]. The SARS-CoV-2. MV-014 – 212 can reduce the SARS-CoV-2 peak shedding in the monkey’s nose by more than 200-fold [320–324]. Inactivated vaccines contain whole viruses that have been killed with chemicals (Formalin or beta-propiolactone), UV light, and heat which cannot cause disease, even in immunosuppressed individuals. Since, inactivated vaccines do not have a durable and long-lasting immune response as live attenuated vaccines, they usually require repeated doses or booster doses, and often adjuvant such as aluminum salts should be added to the vaccine. Meanwhile, formalin inactivation compared to other inactivation methods is associated with a harmful Th2 skewing immune response [322]. The Covaxin, CoronaVac, BBIBP-CorV, and WIBP-CorV are inactivated vaccines approved or authorized for emergency use in several other countries (Table 3). Jara A et al.’s study in Chile on the effectiveness of an inactivated CoronaVac on 10.2 million persons aged 16 years and older has shown that the adjusted vaccine effectiveness for prevention of Covid-19, hospitalization, ICU admission, and prevention of COVID-19-related death has been 65.9%, 87.5%, 90.3%, and 86.3%, respectively [323].

Recombinant viral vector vaccines expressing SARS-CoV S protein include recombinant adenovirus (Ad) vectors, vaccinia virus, measles, Newcastle disease virus (NCD), and vesicular stomatitis virus (VSV) [318,324]. However, recombinant viral vector vaccines are safe and induce high cellular and humoral immune responses, possibly present pre-existing immunity. The Convidecia (Ad5-nCoV), Janssen Janssen (Ad26.COV2.S), Sputnik V (Ad26 and Ad5), Oxford-AstraZeneca AZD1222 (previously ChAdOx1), are recombinant viral vectors that were approved or authorized for emergency use in other countries. Also, Coroflu (Influenza A virus Vector), and Dendritic cells (DCs) or aAPC (artificial antigen-presenting cell) modified with a lentiviral vector expressing synthetic minigenes, are vaccine candidates in phase 1 clinical trial and preclinical stage, respectively (Table 3).

Recombinant Viral protein vaccines include subunits or virus-like particle vaccines. Subunit vaccines are highly safe and can induce cellular and humoral immune responses, but these vaccines have a high cost, lower immunogenicity, and require repeated doses and adjuvants. Virus-like particles (VLPs) are self-assembled viral protein complexes and lack the viral genome. VLPs are safe and efficient tools for studying the pathogenic mechanisms of virus infection and evaluating the efficiency of the vaccine [46]. S protein or RBD subunit vaccines as well as replicating or non-replicating vector vaccines expressing S protein or the RBD provide antigenic proteins to motivate antibody and T-cell immune responses [317–319,324] (Table 3).

Nucleic acid vaccines include DNA plasmids such as INO-4800, ZyCoV-D, and AG0302 or mRNA vaccines such as BNT162 mRNA (BioNTech - Pfizer) and mRNA-1273 (Moderna) encode S or RBD proteins. Although DNA vector vaccines may be safe, stable, and produced rapidly, their immune responses in humans are lower, and repeated doses may cause toxicity. Meanwhile, mRNA vaccines are easier to design, transiently expressed, and quickly induce strong immune responses and do not integrate into the host genome, but are highly unstable under physiological conditions [325]. Delivery of the mRNA vaccine is enhanced by using lipid nanoparticles for intramuscular (IM) or intradermal administration [317,326]. Adding S protein to synthetic nucleic acid vaccines causes booster vaccines, and these vaccines, as mentioned before, are candidate vaccines based on criteria.

BioNTech - Pfizer, Moderna, and Johnson & Johnson are the developed COVID-19 vaccines that FDA authorized for emergency use [327]. In addition to these vaccines, WHO has approved AstraZeneca, Sputnik V, Sinopharm-BBIBP, Novavax, and CoronaVac vaccines for Emergency Use Listing (EUL). Most candidate vaccines are represented on the induction of antibodies and cell-mediated immune responses in the animal models [328]. The protective monoclonal antibodies (mAbs) against the target viral proteins can be essential to map the epitopes that guide vaccine design and provide passive immunoprophylaxis for infected patients by COVID-19 [329] (Table 3). Deborah Steensels et al.’s study on antibody response against SARS-CoV-2 RBD following the second dose vaccination with BioNTech - Pfizer and Moderna has shown that the antibody titers after vaccination by Moderna were higher than Alpha [330].

Modern vaccine (4 weeks vs. 3 weeks). Lack of evaluation of cellular immunity and neutralizing antibodies has been one of the limitations of this study [330]. There are several studies on the efficiency of COVID-19 vaccines against emerging variants. Studies have shown that the Moderna COVID-19 vaccine protects neutralizing activity against Alpha (previously known as B.1.1.7 or S01Y.V1) and Beta (previously known as B.1.351 or 501Y.V2) Variants [331]. The beta variant has a more significant reduction to both mAbs and convalescent sera than Alpha [332]. Mutation N501Y within the RBD increases the binding affinity to ACE-2 and, in combination with P681H mutation, increases the viral fusion [333] and virus transmission [334]. A study by Jamie Lopez Bernal et al. showed that the efficacy of the Pfizer vaccine in individuals after the
second dose was 93.7% against the alpha strain and 88% against the B.1.617.2 (Delta) strain [335].

The convalescent plasma of patients infected with non-501Y.V3 variants could neutralize the gamma variant (formerly known as 20J/501Y.V3, P.1 or B.1.1.281.1) 6-fold reduced than non-501Y.V3 isolates compared to non-501Y.V3 isolates [336]. Souza WM et al.’s study showed that plasma from inactivated CoronaVac vaccine neutralizes 501Y.V3 isolates less effectively than non-501Y.V3. [336]. Pragya Yadav et al.’s study has shown that convalescent sera of the COVID-19 patients infected with Indian Delta Variant (previously known as B.1.617) and recipients of BBV152 (Covaxin) were able to neutralize this variant [337]. Andrade, V.M., et al.’s study showed that the INO-4800 vaccine could induce neutralizing antibodies against Alpha and Gamma variants, with reduced levels detected against Beta variant [338].

There are some controversies reported on the adenoviral-based SARS COV-2 vaccine. Shabar A et al.’s study showed that the AstraZeneca AZD1222 (ChAdOx1 nCoV-19 vaccine) does not protect against a predominant variant B.1.351, and mild-to-moderate COVID-19 infection developed in 19 of 750 vaccine recipients (2.5%). The efficacy of the ChAdOx1 nCoV-19 vaccine against Beta (B.1.351) variant was 10.4% in participants infected with this variant [339]. However, because AstraZeneca only needs to be refrigerated rather than mRNA vaccines that need frozen, it can be used far more widely. Katherine R. W. Emary et al.’s study showed that the efficacy of the AstraZeneca vaccine against the Alpha variant was similar to other lineages [340]. Also, Jamie Lopez Bernal et al.’s study revealed that the effectiveness of the ChAdOx1 nCoV-19 vaccine after the second dose was 74% and 67% for the alpha and delta strains, respectively [335]. As for the Sputnik V, Ikegami S et al.’s study has shown that Sputnik V is unable to neutralize vesicular stomatitis virus (VSV) encoding S from Beta variant of SARS COV-2 instead of VSV-G (rVSV-CoV2-S: B.1.351.) and moderately reduced activity against S from Alpha in a clonal HEK-293 T ACE-2 TMPRSS2 cell line [341]. Wibmer CK et al.’s study showed that Beta has 93% resistance to South African COVID-19 donor mAbs and convalescent plasma samples [342]. Jerald Sadof et al.’s study showed that the efficiency of Janssen vaccine (Ad26.COV2.S) (5 × 10^10 viral particles in a single dose) against Beta variant in moderate to severe and severe–critical COVID-19 is 64.0% and 81.7%, respectively at least 28 days after administration [343]. Meanwhile, Galit Alter et al. in their study revealed that median pseudovirus neutralizing antibody titers and Median binding antibody titers 71 days following vaccination with Ad26.COV2.S vaccine was 5.0- and 3.3-fold lower and 2.9- and 2.7-fold lower against the Beta and Gamma variants, respectively [344].

In the case of the adenoviral-based platform SARS COV-2 vaccines, studies have shown that in rare cases AstraZeneca and Johnson & Johnson vaccines cause blood clots and cerebral and intestinal venous thrombosis with thrombocytopenia syndrome (TTS) which is termed Vaccine-Induced Thrombocytopenia (VITT) or autoimmune heparin-induced thrombocytopenia (HIT) (low platelets count, <150,000 per microliter) [345] and induced by platelet-activating antibodies against platelet factor 4 (PF4) [346], which mimics thrombocytopenia. This side effect has been reported in four cases per million people vaccinated with AstraZeneca [347–348] and nine cases per 1 million doses for the Janssen COVID-19 vaccine [349–350]. As previously mentioned, binding of SARS-Cov-2 S1 protein (in both natural viral infection and DNA spike protein vaccines) to ACE-2 receptor by clumping and reduction of ACE-2 in the host, leads to a decrease in the conversion of angiotensin 2 to angiotensin 1–7 and an increase in the level of angiotensin 2, which ultimately leads to vasoconstriction, thrombosis, and tissue damage [110]. This process is associated with high viral copy numbers or high viral capsid proteins expressed by DNA vaccines that can damage the alveolar endothelial and lead to the circulation of viral capsid proteins to the ACE-2 + endothelium which are more commonly found in the brain [351]. In the case of AstraZeneca and Johnson vaccines, these side effects are probably due to the high copy number of adenovirus particles used per dose of the vaccine (5 × 10^{10} viral particles in a single dose). On the other hand, after the first exposure to a vaccine by decreasing the vaccine antigen over time for producing the higher-affinity antibody and immune memory in the affinity maturation process, just those B cells population that has fit interaction with antigenic epitopes are stimulated, that needs long time interval between the primary series and booster of vaccine [352]. For example, as for AstraZeneca, it was revealed that longer prime-boost interval increased the vaccine efficacy from 55-1% in a short interval (<6 weeks) to 81-3% in a long boost interval (>2 weeks) [353]. However, using a single dose of vaccine or a further increase in the distance between two doses may lead to the formation of antibody-selected variants due to competition between neutralizing antibodies and the virus. Therefore, using a highly stable single dose of vaccine or, using a fewer viral particles in each dose or other vaccines as a booster dose can significantly improve the chances of successful vaccination.

Regarding intranasal vaccines such as covaxin (BBV154), COVI-VAC, and Coroflu, and Meissa Vaccine (MV-014–212), it should be mentioned that these vaccines, in addition to the ease of administration, can stimulate broad immune responses, including neutralizing IgG, mucosal IgA, and T cell responses. Moreover, due to mucosal immunity in the nasal mucosa, these vaccines have an essential role in blocking both COVID-19 infection and SARS COV-2 transmission [354].

9. Conclusion

Most people infected with COVID-19 will have only a mild illness. The elderly and those with chronic health conditions remain the most vulnerable to severe illness derive from COVID-19. More than one year and six months after the pandemic of COVID-19, the number of cases and mortality rates are still rising in the world due to asymptomatic transmission. COVID-19 pandemic continuity depends on many things, including researchers’ work for effective treatments, vaccine development and the public’s effort to slow its spread by social distancing and wearing masks [392]. Although there is no specific treatment for COVID-19, several clinical trials of antiviral drugs are underway. Nevertheless, more studies in the SARS-CoV-2 structure and valid trials with a larger sample size are required. According to new studies, some promising evidence has been observed for the use of Corticosteroids and interleukin-6 inhibitors. However, Dexamethasone does not prevent COVID-19 and even increases the susceptibility of viral infections by weakening the immune system. There was also no evidence of the efficacy of chloroquine, hydroxychloroquine, lopinavir, ritonavir and remdesivir. Other medicines, including favipiravir, cytokine inhibitors, interferons, Cytosorb, Stem cells, antiocoagulants, and monoclonal antibodies, have had conflicting results. However, improving the immune system by proper nutrition, consuming vitamins and micronutrients can help us protect ourselves against SARS-CoV-2 infection. Hitherto, more than 206 vaccine projects are in various stages of development, and several vaccines are expected to be licensed by the end of 2021. However, it is possible that due to the possibility of genetic changes in the Coronavirus, a new strain of the virus will develop as a result of the virus circulating around the world. Therefore, after the large-scale production of vaccines, effectiveness against emerging variants, then transport, storage, availability, and distribution of the vaccines are the main vaccine properties that should be considered in assessing vaccine efficacy. Also, control of new SARS-CoV-2 variants will be obtained from updated vaccines. The increased risk of SARS-CoV-2 infection can be attributed to the high transmissibility of delta strain and its escape from vaccine-induced immunity, as well as the increased exposure of vaccinated people to unvaccinated individuals in public places. Altogether, by adherence to COVID-19 public health guidelines, using effective drugs, quick and extensive vaccination of all people, first the elderly or people with underlying diseases, using a booster dose, and recruiting vaccinated and young people in activities that require more community participation can effectively interrupt the transmission of the virus and
reduce disease burden.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The authors would like to express their gratitude to the Hepatitis and AIDS department of Pasteur Institute of Iran and the virology department of Iran University of Medical Sciences for their kind assistance and support.

References

[1] WHO, WHO Coronavirus (COVID-19) Dashboard, 2021. https://covid19.who.int/.

[2] L. Zhang, Y. Liu, Potential interventions for novel coronavirus in China: A systematic review, J. Med. Virol. 92 (5) (2020) 479–490.

[3] D.A. Brian, R.S. Bartic, Coronavirus genome structure and replication, Curr. Top. Microbiol. Immunol. 287 (2005) 1–30.

[4] X. Ou, Y. Liu, X. Lei, P. Di, M. Li, L. Ren, L. Guo, R. Guo, T. Chen, J. Hu, Characterization of spike glycoprotein of SARS-CoV-2 virus entry and its immune cross-reactivity with SARS-CoV, J. Virol. 111 (1) (2021) 1–12.

[5] D. Cucinotta, M. Vanelli, WHO declares COVID-19 a pandemic, Acta bio-medica: Atenei Parmensis 91 (1) (2020) 157–160.

[6] H.A. Rotan, S.N. Byrareddy, The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak, J. Autoimmun. 102/233 (2020).

[7] A.G. Harrison, T. Lin, P. Wang, Mechanisms of SARS-CoV-2 Transmission and Pathogenesis, Trends Microbiol. 41 (12) (2020) 1100–1115.

[8] J. Borges do Nascimento, N. Cacie, H.M. Albuquerque, T.C. Von Groote, U. Jayarajah, I. Weerasekara, M.A. Esfahani, V.T. Civile, A. Marusic, A. Jeroncic, Novel coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis, Journal of clinical medicine 9(4) (2020) 941.

[9] N. Perruzetto, G. Vincenzo, O. Esgolli, E. Petersen, COVID-19, SARS and MERS: are they closely related? Clin. Microbiol. Infect. Off. Publ. European Soc. Clin. Microbiol. Infect. Dis. 26 (6) (2020) 729–734.

[10] J.-J. Zhang, X. Dong, Y.-Y. Cao, Y.-D. Yuan, Y.-B. Yang, Y.-Q. Yan, C.A. Aksit, Y.-D. Gao, Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China, Allergy 75 (7) (2020) 1730–1741.

[11] X.-W. Xu, X.-X. Xu, X.-G. Jiang, K.-J. Xu, L.-J. Ying, C.-L. Ma, S.-B. Li, H.-Y. Wang, S. Zhang, H.-N. Gao, J.-F. Sheng, H.-L. Cai, Y.-Q. Qu, L.-J. Li, Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series, BMJ 368 (m606).

[12] D. McGonagle, C. Bridgewood, A.V. Ramana, J.F.M. Meaney, A. Watad, COVID-19: a practical and vaccine update, Lancet Respir. Med. 8 (1) (2020) 1–10.

[13] C. Danese, L. Peyrin-Biroulet, Diarrhea During COVID-19 in hospitalized Patients With COVID-19 in Wuhan, China, JAMA Cardiology 5 (7) (2020) 766–773.

[14] T. Yu, Y. Wang, S. Pan, X. Zou, S. Yuan, Y. Shang, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir. Med. 8 (5) (2020) 475–481.

[15] K. Lingappan, H. Karmouty-Quinatna, J. Davies, B. Akkanti, M.T. Harting, Understanding the age divide in COVID-19: why are children overwhelmingly spared? American J. Physiol. Lung Cell Mol. Physiol. 319 (1) (2020) L39–L44.
[46] J. Zhang, H. Zeng, J. Gu, H. Li, L. Zeng, Q. Zou, Progress and prospects on vaccine development against SARS-CoV-2, Vaccines 9 (2) (2020) 155.
[47] Y. Kim, R. Jeziorowski, M.J. Malave, M. Willamowski, M. Endres, A. Godzik, K. Michalska, A. Joachimiak, Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2, Protein Sci. Publicat. Protein Soc. 29 (7) (2020) 1596–1605.
[48] A. Shannon, N.T.E. B, L. Selisko, E. Eydoux, K. Alvarez, J.C. Guillomet, E. Decroly, O. Peersen, F. Ferron, B. Canard, Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites, Antiviral Res. 178 (2020), 104775.
[49] R.A. Khailany, M. Safdar, M. Ozaslan, Genomic characterization of a novel SARS-CoV-2, Gene Rep 19 (2020), 100682.
[50] M. Rokni, V. Ghaemz, Z. Tavakoli, Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS, Rev. Med. Virol. 30 (3) (2020), e2107.
[51] J. Gribble, J.L. Stevens, M.L. Agostini, J. Anderson-Daniels, J.D. Chappell, X. Lu, R.A. Khailany, M. Safdar, M. Ozaslan, Genomic characterization of a novel SARS-CoV-2, Gene Rep 19 (2020), 100682.
[52] A. Poon, C. Davis, L. Piccoli, D.J. Pascall, J. Dillen, S. Lytras, N. Hengartner, E.E. Giorgi, On the origin and continuing evolution of SARS-CoV-2, Natl. Sci. Rev. 7 (6) (2020) 1012–1023.
[53] P. Forster, L. Forster, C. Renfrey, M. Forster, Phylogenetic network analysis of SARS-CoV-2 genomes, Proc. Natl. Acad. Sci. 117 (17) (2020) 9241–9245.
[54] E.B. Hodcroft, D.B. Domman, D.J. Snyder, K.H.D. Crawford, J.D. Bloom, Prospective mapping of viral mutations that escape receptor binding domain antibodies, bioRxiv (2020) 2020.11.04.355842.
[55] H.W. Virgin, A. Telenti, D. Corti, D.L. Robertson, G. Snell, The circulating SARS-CoV-2 (hCoV-19) Mutation Reports, 2020. https://outbreak.info/.
[56] T. Koyama, D. Platt, L. Parida, Variant analysis of SARS-CoV-2 genomes, Bull. World Health Organ. 107 (11) (2019) 495.
[57] A. Nagy, S. Pongor, B. György, Different mutations in SARS-CoV-2 associate with severe and mild outcome, Int. J. Antimicrob. Agents 57 (2) (2021), 106272.
[58] J. Chen, R. Wang, M. Wang, G.-W. Wei, Mutations Strengthened SARS-CoV-2 Infectivity, J. Virol. 94 (12) (2020), 1–8.
[59] L. Carrilero, L.R. Green, D.C. Groves, K.J. Johnson, A.J. Keeley, B.B. Lindsey, P. Partridge, C.M. Evans, T.M. Freeman, T.I. de Silva, A. Angyal, R.L. Brown, H. Dingens, J.Z. Li, Dingens, J.Z. Li, J.D. Bloom, Prospective mapping of viral mutations that escape receptor binding domain antibodies, bioRxiv (2020) 2020.11.04.355842.
[60] E.B. Hodcroft, A.L. Routh, M.R. Denison, The coronavirus proofreading exonuclease achieves extensive viral recombination, PLoS Pathog. 17 (1) (2021), e1009226.
[61] M. Rokni, V. Ghaemz, Z. Tavakoli, Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS, Rev. Med. Virol. 30 (3) (2020), e2107.
[62] J.A. Plante, Y. Liu, J. Liu, H. Xia, B.A. Johnson, K.G. Lokugamage, X. Zhang, A. E. Muratov, J. Zou, C.R. Fontes-Garfias, Spike mutation D614G alters SARS-CoV-2 immunity, bioRxiv (2020) 2020.11.04.355842.
[63] J.A. Benguerem, M.V.T. Tran, B. Zhao, Y. Zhu, J. Cui, J. Lu, On the origin and continuing evolution of SARS-CoV-2, Natl. Sci. Rev. 7 (6) (2020) 1012–1023.
[64] T. Koyama, D. Platt, L. Parida, Variant analysis of SARS-CoV-2 genomes, Bull. World Health Organ. 107 (11) (2019) 495.
[65] C. Gaebler, Z. Wang, J.C.C. Lorenzi, F. Muecksch, S. Finkin, M. Tokuyama, M. Cipolla, C. LaBranche, E.O. Saphire, D.C. Montefiori, Tracking Changes in SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS, Rev. Med. Virol. 30 (3) (2020), e2107.
[66] J.A. Benguerem, M.V.T. Tran, B. Zhao, Y. Zhu, J. Cui, J. Lu, On the origin and continuing evolution of SARS-CoV-2, Natl. Sci. Rev. 7 (6) (2020) 1012–1023.
[67] C. Gaebler, Z. Wang, J.C.C. Lorenzi, F. Muecksch, S. Finkin, M. Tokuyama, M. Cipolla, C. LaBranche, E.O. Saphire, D.C. Montefiori, Tracking Changes in SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS, Rev. Med. Virol. 30 (3) (2020), e2107.
[68] J. Zhang, H. Zeng, J. Gu, H. Li, L. Zeng, Q. Zou, Progress and prospects on vaccine development against SARS-CoV-2, Vaccines 9 (2) (2020) 155.
[69] Y. Kim, R. Jeziorowski, M.J. Malave, M. Willamowski, M. Endres, A. Godzik, K. Michalska, A. Joachimiak, Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2, Protein Sci. Publicat. Protein Soc. 29 (7) (2020) 1596–1605.
[70] A. Shannon, N.T.E. B, L. Selisko, E. Eydoux, K. Alvarez, J.C. Guillomet, E. Decroly, O. Peersen, F. Ferron, B. Canard, Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites, Antiviral Res. 178 (2020), 104775.
[71] R.A. Khailany, M. Safdar, M. Ozaslan, Genomic characterization of a novel SARS-CoV-2, Gene Rep 19 (2020), 100682.
exploratory analysis of a randomised controlled trial, The Lancet 397(10282) (2021) 1351-1362.

S. Xia, Y. Zhang, Y. Wang, H. Wang, Y. Yang, G.F. Gao, W. Tan, G. Wu, M. Xu, B. Huang, L. Dai, H. Wang, Z. Hu, X. Yang, W. Tan, G. F. Gao, Neutralization of SARS-CoV-2 Spike variant, medRxiv (2021) 2021.03.31.21254660.

C.K. Wibmer, J. Laurence, G. Nuovo, Severe COVID-19: A multifaceted viral vasculopathy in humans, Nature 596 (7871) (2021) 268–272.

K. Kupfersmidt, G. Vogel, Vaccine link to serious clotting disorder firms up, Science 372 (6593) (2021) 220–221.

A. Greinacher, T. Thiele, T.E. Warkentin, K. Weisser, P.A. Kyrle, S. Eichinger, J. Sadoff, M. Le Gars, G. Shukarev, D. Heerwegh, C. Truyers, A.M. de Groot, C.K. Wibmer, F. Ayres, T. Hermanus, M. Madzivhandila, P. Kgagudi, B.E. Lambson, M. Vermeulen, K. van den Berg, T. Rossouw, M. Boswell, V. Ueckermann, S. von Gottberg, C. Cohen, L. Morris, J.N. Bhiman, P.L. Moore, SARS-CoV-2 501Y.V2 escape utilization by South African COVID-19 donor plasma, bioRxiv (2021) 2021.03.18.427166.

J. Sadof, M. Le Gars, G. Shukarev, D. Heerwegh, C. Truyers, A.M. de Groot, J. Stoot, S. Tette, W. Van Damme, I. Leroux-Roels, Safety and immunogenicity of the Ad5-26.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomised, placebo-controlled trial, N. Engl. J. Med. (2020.09.23) 20199604.

G. Alter, J. Yu, J. Liu, A. Chandrashekar, E.N. Borduch, L.H. Tostanoski, K. McMahen, C. Jacob-Dolan, D.R. Martinez, A. Chang, T. Anikoie, M. Li, R. Nikola, K. E. Stephenson, C. Areyo, S. Shin, R. Fields, I. Kaplan, H. Robins, F. Amanat, F. Krammer, R.S. Baric, M. Le Gars, J. Sadof, A.M. de Groot, B. De Heerwegh, F. Sreyuf, M. Dougoth, I. van Hoof, H. Schutekamer, D. H. Barouch, Immunogenicity of Ad5.nCoV/2 virus against SARS-CoV-2 variants in humans, Nature 596 (7871) (2021) 268–272.

A. P. Junqueira-Kipnis, L.R.B. Dos Anjos, L.C.S. Barbosa, A.C. Costa, K.C. M. Borges, A. Cardoso, K.D.M. Ribeiro, S.A.A. Rosa, C.C. Souza, R.C. da Neves, G. Sarraiva, S.M. da Silva, E.A. Silveira, M.F. Rabahi, M.B. Conte, A. Kipnis, BCG vaccination of health workers in Brazil to improve immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial, Trials 21 (1) (2020) 881.

K. Yiharek, G. Abraham, T. Girma, T. Tlahin, M. Woldie, The effect of Bacillus Calmette-Guerin (BCG) vaccine on the risk of Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination, N Engl J Med 384 (22) (2021) 2092–2101.

J. Laurence, G. Nuovo, Severe COVID-19: A multifaceted viral vasculopathy in humans, Nature 596 (7871) (2021) 268–272.

M.E. Pichichero, Vaccine-induced immunologic memory and pace of pathogenesis: predicting the need for boosters, Expert Rev. Vacc. 7 (9) (2008) 891–897.

M. Vogsey, S.A.C. Lemes, S.A. Madhi, L.Y. Weck, P.M. Foldegati, P.K. Aley, B. Angus, V.L. Baillie, S.L. Barnabas, Q.E. Bhorat, Single-dose administration and immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine X. Yang, Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: an exploratory analysis of a randomised controlled trial, The Lancet 397 (10240) (2020) 1845–1854.
[385] L.R. Baden, H.M. El Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D. Diemert, S. A. Spector, N. Rouphael, C.B. Creech, Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine, N. Engl. J. Med. 384 (5) (2021) 403–416.

[386] P. Tebas, S. Yang, J.D. Boyer, E.L. Reuschel, A. Patel, A. Christensen-Quick, V. M. Andrade, M.P. Morrow, K. Kravyuk, J. Agnes, M. Purwar, A. Sylvester, J. Pawlacki, E. Gillespie, I. Maricic, F.I. Zaidi, K.Y. Kim, Y. Dia, D. Frase, P. Pezzoli, K. Schulthes, T.R.F. Smith, S.J. Ramos, T. McMullan, K. Buttigieg, M. W. Carroll, J. Ervin, M.C. Diehl, E. Blackwood, M.P. Mammen, J. Lee, M.J. Dallas, A.S. Brown, J.E. Shea, J.J. Kim, D.B. Weiner, K.E. Broderick, L.M. Humeau, Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial, EClinicalMedicine 31 (2021).

[387] A. Patel, J. Walters, E.L. Reuschel, K. Schulthes, E. Parzych, E.N. Gary, I. Maricic, M. Purwar, Z. Eblimit, S.N. Walker, D. Guimet, P. Bhojnagarwala, A. Doan, Z. Xu, D. Elwood, S.M. Reeder, I. Pesant, K.Y. Kim, A. Cook, N. Chokkalingam, B. Finneyfrock, E. Tello-Ruiz, A. Dodson, J. Choi, A. Generotti, J. Harrison, N.J. Tursi, V.M. Andrade, Y. Dia, F.I. Zaidi, H. Andersen, M.G. Lewis, K. Muthumani, J. J. Kim, D.W. Kulp, L.M. Humeau, S. Ramos, T.R.F. Smith, D.B. Weiner, K.E. Broderick, Intradermal-delivered DNA vaccine provides ananmestic protection in a rhesus macaque SARS-CoV-2 challenge model, bioRxiv (2020) 2020.07.28.225649.

[388] T.R.F. Smith, A. Patel, S. Ramos, D. Elwood, X. Zhu, J. Yan, E.N. Gary, S. N. Walker, K. Schulthes, M. Purwar, Z. Xu, J. Walters, P. Bhojnagarwala, M. Yang, N. Chokkalingam, P. Pezzoli, E. Parzych, E.L. Reuschel, A. Doan, N. Tursi, M. Vasquez, J. Choi, E. Tello-Ruiz, I. Maricic, M.A. Bah, Y. Wu, D. Amante, D.H. Park, Y. Dia, A.R. Ali, F.I. Zaidi, A. Generotti, K.Y. Kim, T. A. Herring, S. Reeder, V.M. Andrade, K. Buttigieg, G. Zhao, J.-M. Wu, D. Li, L. Bao, J. Liu, W. Deng, C. Qin, A.S. Brown, M. Khoshnejad, N. Wang, J. Chu, D. Wrapp, J.S. McLellan, K. Muthumani, B. Wang, M.W. Carroll, J.J. Kim, J. Boyer, D.W. Kulp, L.M.P.F. Humeau, D.B. Weiner, K.E. Broderick, Immunogenicity of a DNA vaccine candidate for COVID-19, Nat. Commun. 11 (1) (2020) 2601.

[389] D.R. Mittal, Novel Corona Virus-2019-nCov vaccine by intradermal route in healthy subjects, 2020. http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=51254&EncId=&userName=ZyCoV-D.

[390] S.P. Kaur, V. Gupta, COVID-19 Vaccine: A comprehensive status report, Virus Res. 288 (2020) 198114.

[391] Phase II/III Study of COVID-19 DNA Vaccine (AG0302-COVID19), ClinicalTrials.gov, 2020.

[392] R. Si, Y. Yao, X. Zhang, Q. Lu, N. Aziz, Investigating the Links Between Vaccination Against COVID-19 and Public Attitudes Toward Protective Countermeasures: Implications for Public Health Front. Public Health 9 (1040) (2021).